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1 SUMMARY 
Modification of RNA is an important function in the immunological discrimination between 
self and non-self RNA. Naturally occurring RNA modifications have been identified that 
suppress activation of the innate immune response, e.g. 2’O-methylation of the ribose 
backbone. It has already been shown that incorporation of 2’O-methylation in siRNA abrogates 
TLR7-dependent interferon-alpha production in human plasmacytoid dendritic cells (pDCs). 
In the present study, a native bacterial tRNA with 2’O-methylation at position G18 was 
analysed. It was found that the 2’O-methylation not only made the tRNA non-stimulatory, but 
also led to dominant inhibitory effects. Thus, this modification impaired immunostimulation 
by RNA species that would otherwise have been stimulatory. Further analysis revealed that 
not only was interferon alpha production by pDCs via TLR7 suppressed, but also secretion of 
pro-inflammatory cytokines by monocytes, including IL12p40 and TNF. Monocytes express a 
different subset of nucleic acid-sensing receptors, indicating that 2’O-methylated RNA 
influences the stimulation of different receptors. Analysis of other TLR ligands showed that 
the inhibitory effect was specific for stimulation by RNA but it was not observed for R848, a 
synthetic small molecule agonist of TLR7/8, or other TLR ligands. Investigation of the 
signalling pathway in response to RNA stimulation showed that modified, inhibitory RNA 
suppresses TLR stimulation at proximal levels. Preliminary binding studies indicated that 
2’O-methylated RNA can bind directly to TLR7; it does not induce signalling but displaces 
unmethylated stimulatory RNA. As 2’O-methylation of tRNA at position G18 is found in 
tRNAs from many species and the neighbouring sequences are conserved, the influence of 
location and the whole sequence motif itself were investigated. The location of the  
2’O-modification turned out to be of minor importance, but the inhibitory capacity of 
modified tRNA was influenced by the sequence of the motif. The sequence motif DmR was 
found to be necessary for immunosilencing of the tRNA, where D is a base other than 
cytosine with a 2’O-methyl position in the ribose of the nucleoside and R is a purine (adenine 
or guanine) immediately upstream of the methylation (position +1). 
Together, the results show that 2’O-methylation of RNA in a defined sequence motif abrogates 
immunostimulation in different cell types. Naturally occurring RNA modifications serve to 
distinguish self RNA from foreign RNA. The results from this thesis can be used to reduce 
immunostimulation by any RNA when immune stimulation is not intended. 
Zusammenfassung 
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2 ZUSAMMENFASSUNG 
Natürlich vorkommende Modifikationen spielen eine wichtige Rolle bei der Unterscheidung 
zwischen eigener und fremder RNA. Verschiedene Modifikationen, die in der Lage sind, eine 
Immunantwort zu unterdrücken, wurden identifiziert. Eine von ihnen ist die 2’O-Methylierung 
der Ribose, welche, eingebaut in siRNAs, in der Lage ist die Interferon-alpha Produktion von 
plasmacytoiden Dendritischen Zellen (pDCs) durch TLR7-Aktivierung zu unterdrücken. In 
der vorliegenden Arbeit wurde eine bakterielle tRNA untersucht, die an der Position G18 eine 
natürlich vorkommende 2’O-Methylierung aufweist. Diese Modifikation führte nicht nur dazu, 
dass die tRNA alleine keine Interferon-alpha Produktion mehr aktiviert, sondern diese 
modifizierte tRNA und Bruchstücke daraus sind auch in der Lage, die Aktivierung durch 
stimulative RNA zu inhibieren. Es wurde weiter gezeigt, dass diese Inhibition nicht nur die 
Produktion von Interferon-alpha aus pDCs über TLR7 unterdrückt, sondern auch anderer pro-
inflammatorischer Zytokine wie IL12p40 und TNF aus Monozyten, welche andere Nukleinsäure-
erkennende Rezeptoren als pDCs exprimieren. Dies weist darauf hin, dass die Stimulation 
verschiedener Rezeptoren durch modifizierte RNA unterdrückt werden kann. Der Effekt ist 
allerdings spezifisch für die Stimulation durch RNA, da die Stimulation durch R848, einen 
sythtischen TLR7/8 Agonisten, oder durch andere TLR Liganden nicht inhibiert werden 
konnte. Untersuchungen auf der Ebene der Signalweiterleitung zeigten eine Inhibition durch 
modifizierte RNA bereits proximal in der Signalkaskade. Daher wurde die direkte Bindung 
von 2’O-methylierter RNA an TLR7 untersucht. Erste Studien zeigten, dass 2’O-methylierte 
RNA direkt an den Rezeptor bindet und nicht modifizierte, stimulative RNA verdrängt. Da 
2’O-Methylierung an G18 in verschiedenen tRNAs beobachtet wurde, wurde der Einfluss von 
Position und Sequenzmotiv auf den inhibitorischen Effekt untersucht. Dabei konnte gezeigt 
werden, dass weniger die Lokalisation der Modifikation innerhalb der tRNA sondern 
vielmehr die Sequenz um die Modifikation den Effekt beeinflusst. Das Sequenzmotive DmR 
wurde als das ausschlaggebende für die Inhibition identifiziert. Dabei ist D eine beliebige Base 
außer Cytosin mit der 2’O-Methylierung und R ist ein Purin an der Position +1 in 3‘ Richtung 
von der 2’O-methylierten Position. Zusammenfassend hat diese Studie gezeigt, dass RNA mit 
einer 2‘O-Methylierung in einem definierten Sequenzkontext, die Immunstimulation in 
verschiedenen Zellarten unterdrückt. Natürlich vorkommende 2’O-Methylierungen werden zur 
Selbst/Fremd Diskriminierung verwendet. Mit den Ergebnissen dieser Arbeit können durch 
Einführung von 2’O-Methylierungen beliebige RNA Spezies inhibierend gemacht werden. 
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3 INTRODUCTION 
The immune system is important for the recognition and clearance of pathogens. To function 
in a proper way, the immune system has to cope with a wide range of pathogens ˗ from viruses 
and bacteria to fungi and parasites. Thus, an important characteristic is to be able to 
distinguish between self and foreign structures. The immune system has two main parts, the 
innate immune system and the adaptive immune system. In evolutionary terms, the innate 
immune system is the older of the two. It is found in all animals and plants, and is the 
organism’s first line of defence. The adaptive immune system is activated through antigen-
presenting cells of the innate immune system and is based on clonal selection of lymphocytes. 
The response is specific and results in formation of immune memory. 
3.1 Recognition within the innate immune system 
Invading pathogens must be quickly recognised by the immune system. This important 
function is fulfilled by germline-encoded receptors, which have been identified as pattern 
recognition receptors (PRRs). PRRs detect highly conserved components of microbes, so-
called pathogen-associated molecular patterns (PAMPs) 2. PAMPs are essential to microbes, 
and they cannot be easily manipulated 2,3. Thus, a broad range of pathogens can be recognised 
with a limited number of different receptors 2,4,5.  
PRRs fall into different groups according to their molecular structure: Toll-like receptors 
(TLRs), retinoic acid inducible gene-I (RIG-I)-like receptors (RLRs), nucleotide-binding and 
oligomerization domain (NOD)-like receptors (NLRs), interferon-inducible protein (Ifi), absent 
in melanoma 2 (Aim2)-like receptors, and receptors with C-type binding domains (CLRs) 6–11. 
These receptors are located at the cell surface, in intracellular compartments, or in the cytosol. 
All of them are composed of a ligand binding domain and a signalling domain. Upon binding 
of the ligand, the signalling domain is activated mostly by dimerisation, oligomerization, or 
conformational changes. Then the signalling domain recruits adapter proteins to initiate 
intracellular signalling.   
Cytosolic receptors are expressed in most cell types, while TLRs are mostly expressed in 
immune cells. Innate immune cells include phagocytic cells, antigen-presenting cells, natural 
killer cells, mast cells, and platelets. Phagocytic cells are mainly involved in the defence against 
extracellular microbes. The group of phagocytic cells includes monocytes, macrophages, and 
polymorphonuclear granulocytes. Monocytes circulate in the blood but can be recruited into 
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various tissues upon infection, where they differentiate into macrophages. Macrophages can 
also be found as steady-state cells in most tissues. Antigen-presenting cells are another group 
of immune cells. They fall into different groups, depending on their origin and function. One 
group is made up of myeloid dendritic cells (DCs). They have a myeloid progenitor and 
express interleukin 8 (IL8) and IL12 as characteristic cytokines. On the other hand, 
plasmacytoid DCs (pDCs) have a lymphoid progenitor and mainly produce type-I interferons 
(IFNs).   
3.1.1 Toll-like receptors 
TLRs can activate the immune response to bacterial, fungal, and viral infections. They are 
homologous to the protein Toll in Drosophila melanogaster. Toll was first described by 
Christiane Nüsslein-Volhard in 1985 concerning its role in embryonic development 12.  
In 1996, Jules A. Hoffmann and colleagues ascribed to Toll a role in immunity 13 when they 
observed that a fruit fly mutated in toll was no longer able to eliminate fungal infections.  
In 1998, Bruce Beutler and colleagues discovered the first ligand for a mammalian TLR, i.e. 
lipopolysaccharide (LPS) as ligand for TLR4 14. Both Hoffmann and Beutler were honoured 
with the Nobel Prize in Medicine and Physiology in 2011 for “their discoveries concerning 
the activation of innate immunity” (The Nobel Assembly at Karolinska Institutet) 15.  
Currently, ten TLRs are known in humans (TLR1–TLR10), whereas in the murine system  
12 receptors (TLR1–TLR9 and TLR11–TLR13) are known 16. These are either expressed on 
the cell surface (TLR1, 2, 4, 5, 6, and 10) or in intracellular compartments (TLR3, 7, 8, and 
9), namely endosomes 17–20. Each TLR binds to a distinct family of microbial molecules and 
activates immune responses 21,22. Activated TLRs form homo- or heterodimers. TLR2 builds 
heterodimers with TLR1 or TLR6 and recognises bacterial lipoproteins 23–26. TLR4 complexes 
with MD2 to sense LPS 14,27, and homodimers of TLR5 recognise the depolymerized form of 
flagellin 28. The receptors TLR3, TLR7–TLR9, and TLR13 (the latter only in the murine 
system) sense various forms of bacterial and viral nucleic acids 29–37. All the human TLRs 
with their ligands and adapter molecules are shown in Figure 3-1A.  
Each TLR consists of an extracellular or luminal domain and an intracellular/cytosolic 
domain, which are connected by a transmembrane domain. The extracellular/luminal domain 
of TLRs forms a characteristic horseshoe-like structure of leucine-rich repeats (LRRs)  
˗ including some irregular loops which are thought to stick out from the LRR backbone, and 
which are important for ligand binding 38–41.   
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The cytosolic domains of all TLRs share a TIR (Toll/interleukin-1 receptor) domain.  
This domain is also present in several signalling adapters. Activation of the receptor by ligand 
binding induces aggregation of the receptor with its adapter molecules mediated by homo- 
and heterotypic interaction between the TIR domains of receptor and adapter molecule 42–47. 
In the human system, five TIR-domain-containing adapter molecules are involved: MyD88 
(myeloid differentiation primary response gene 88), MAL (MyD88-adapter-like protein), 
TRIF (TIR-domain-containing adapter-inducing interferon-β), TRAM (translocating chain-
associating membrane protein), and SARM (sterile-α and armadillo motif-containing protein) 
48–52
. MyD88 is required for all TLRs except TLR3, which uses TRIF. TLR4 can signal via 
both MyD88 and TRIF. MAL is a bridging adapter essential for MyD88-dependent signalling 
of TLR2 and TLR4. TRAM is a bridging adapter for TRIF, and is necessary for TLR4 
signalling but not for TLR3 signalling. SARM is probably a negative regulator of TLR 
signalling. It interacts with TRIF and therefore blocks its function. In addition to the TIR 
domain, MAL contains an N-terminal phosphatidyl inositol-binding motif and TRAM 
contains an additional myristoylation site. Both motifs are essential for membrane 
localisation of the molecules 53,54. MyD88 contains a death domain required for the 
activation of downstream effectors. Interleukin-1 receptor-associated kinase (IRAK)-4 and 
IRAK1/IRAK2 are downstream kinases recruited directly to the TLR-MyD88 complex.  
The resulting large helical complex has been given the name ‘Myddosome’ (Figure 3-1B) 46. 
The Myddosome has an indispensable role in TLR signalling. Its formation brings the kinase 
domains of the IRAKs into proximity and allows their phosphorylation and activation. In the 
next step, three different pathways are activated: phosphorylation of mitogen-activated  
protein kinase (MAPKs), activation of nuclear factor κB (NFκB) by phosphorylation of  
IκB-α (inhibitor of NFκB), and activation of IRF transcription factors. All three pathways can 
lead to the production of pro-inflammatory cytokines and interferons, which are important 
mediators of inflammation, immune regulation, survival, and proliferation.  
The full-length TLR proteins containing the transmembrane domain are difficult to crystallise. 
Thus, to date, all structural studies have been done with truncated extracellular or intracellular 
domains; no full-length information is yet available. There are indications that activated and 
dimerised TLRs form clusters of higher order in the cell membrane. However, these structures 
have never been characterised in detail, since crystallisation of the whole complex has not yet 
been successful. 
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3.1.2 Cytosolic receptors 
While TLRs are expressed in immune cells such as macrophages and DCs, cytosolic receptors 
such as RLRs and NLRs are also expressed in a broad range of somatic cells. 
The RLR family has three members: RIG-I, MDA5 (melanoma differentiation-associated 
gene 5), and LGP2 (laboratory of genetics and physiology 2). RLRs were originally described 
as being RNA helicases. RIG-I and MDA5 recognise viral RNA and initiate an immune 
response. The activation leads to the production of pro-inflammatory cytokines and type-I 
IFN. A tandem domain of CARD (caspase activation and recruitment domain) is located at the 
N-termini of RIG-I and MDA5; it  acts as a protein interaction motif by associating with 
downstream signalling components 55. The CARD domain is missing in LGP2, so it is still 
being debated whether it functions as a positive or a negative regulator of RLR signalling 55,56.  
The central part of all three members of the RLR family shows some homology to the 
DExD/H box RNA helicase family members, and is responsible for the binding of double-
stranded RNA and for ATP-dependent unwinding 57. The signal following activation of RLRs 
is mediated by mitochondrial antiviral-signalling protein (MAVS, also known as IPS-1, 
VISA, and CARDIF), an adapter molecule with a function analogous to that of MyD88 for 
TLR signalling 58–61. MAVS is attached to the mitochondrial membrane by the C-terminus 
and induces a delayed response of interferon-stimulated genes (ISGs) via IRF3 60. It has also 
been reported to be attached to peroxisomes 62, where it enables the early induction of ISGs 
via interferon regulatory factor 1 (IRF1).  
Fig. 3-1:Toll-like receptor signalling complexes. (A) Different TLRs with recruited signalling 
adapters and ligands. (B) Speculated structure of TLR4-MD2-LPS-Myddosome complex 1. 
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The NLRs are the largest group of cytosolic receptors. They have a tripartite structure, sharing 
high functional and structural similarities with plant resistance genes (R-genes) 6,63–65.  
All NLRs contain a NACHT domain, which is responsible for oligomerization and activation. 
The phylogenetic history of the NACHT domains has been used for classification of NLRs 6. 
The NLR family falls into two groups: NODs and NLRPs 6,63,66. NODs mediate their 
signalling by an N-terminal CARD and they activate NFκB in a way that is similar to TLR and 
RLR signalling 8,64,67. NLRPs, on the other hand, have an N-terminal pyrin effector domain 
and are able to activate caspase-1 6. NLRPs reside in the cytosol in an inactive and repressed 
form. Upon activation, the proteins form multimeric protein complexes, so-called 
inflammasomes, which are composed of the NLRP, an adapter molecule like Asc, and pro-
caspase-1 68–70. Inflammasome formation leads to the proteolytic self-cleavage of pro-caspase-1 
into the active form, which in turn cleaves pro-IL1β and pro-IL18 into the biologically active 
cytokines 71.  
Apart from NLRPs, inflammasome activation can also be induced by Absent in melanoma 2 
(AIM2), which recognises foreign cytoplasmatic double-stranded DNA 72,73.  
STING has been shown to be an important adapter molecule for different cytosolic DNA 
receptors and to be critical for type-I interferon production upon detection of cytosolic DNA 74–77. 
STING is also capable of directly sensing cyclic dinucleotides, which is used by bacteria as a 
second messenger 78–82. Recently, cyclic 2’-5’-linked dinucleotides were found to be sensed 
by STING. They are synthesised by cGAMP synthetase (cGAS) after interaction of the 
enzyme with DNA83–87. 
Other cytosolic receptors that sense DNA are IFI16 and members of the DExD/H box helicase 
family. IFI16 binds DNA in a non-sequence-specific manner through the negatively charged 
sugar-phosphate backbone of the DNA. It is coupled to STING signalling and leads to type-I 
interferon production 88. The family of aspartate-glutamate-any amino acid-aspartate/histidine 
box helicases (DExD/H) contains important players in sensing of DNA. DHX36 and DHX9 
sense CpG-DNA and lead to the production of type-I interferon and of pro-inflammatory 
cytokines, respectively 89,90. 
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3.2 Pathogen-associated molecular patterns 
To identify invading pathogens, the innate immune system senses PAMPs. These molecules 
are highly conserved and expressed by broad classes of pathogens, but they are not expressed 
by the host. Most PAMPs are expressed on the surfaces of microbes ˗ such as lipoteichoic 
acid in gram-positive bacteria and LPS in gram-negative bacteria, which are recognised by 
TLR2 and TLR4 respectively 14,91,92. Nucleic acids are exceptions to this rule. They are 
common to both the host and the pathogen and yet they have important roles in sensing of 
viruses and other microbes. Thus, special mechanisms have evolved to be able to distinguish 
"self" nucleic acids from foreign nucleic acids (see section 3.2.3).  
3.2.1 Recognition of nucleic acids 
Nucleic acids were discovered in 1869 by Friedrich Miescher 93, and they are essential to all 
known forms of life. Two kinds of nucleic acids are known, RNA and DNA, both of which 
are composed of nucleotides (nucleobases, sugar moieties, and phosphate groups). 
RNA is involved in several processes, such as encoding, and the expression and regulation of 
genes. The nucleobase in RNA nucleotides can be adenine, cytosine, guanine, or uracil.  
In addition to the identity of the nucleobase, RNA nucleotides can also differ in modifications 
of the sugar moiety or of the nucleobase. Different types of RNA are known. In a cell, 
mRNA, tRNA, rRNA, and different regulatory RNAs such as miRNA can be found. Most of 
them exist as single-stranded RNA, but some, e.g. tRNAs, have secondary and tertiary 
structure. Moreover, the RNA viruses have a genome of single-stranded or double-stranded 
RNA.  
Recognition of “self” nucleic acids can contribute to autoimmune and auto-inflammatory 
disease (see section 3.2.3). Even so, the benefit of recognising foreign nucleic acid from 
invading pathogens appears to outweigh the negative consequences of possibly reacting to 
“self” nucleic acids.  
3.2.2 Recognition of RNA by TLRs 
Nucleic acid-sensing TLRs are a distinct subfamily of receptors that are uniquely located in 
endosomes 94. Their localisation in endosomes enables recognition during viral uptake, for 
example, because their contact with host-derived RNA is limited under physiological 
conditions. All nucleic acid-sensing TLRs make use of similar signalling cascades and 
intracellular trafficking 95. One group induced germline mutation using N-ethyl-N-nitrosourea 
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in a mouse model. It resulted in a phenotype failing to sense nucleic acids via TLR3, TLR7 
and TLR9, all nucleic acid sensors identified at this time. The mutation was found to be due to 
a missense allele of unc93b1, encoding the 12-membrane-spanning protein Unc93b1 95. 
Unc93b1 is a conserved protein of the endoplasmatic reticulum (ER) that is crucial for 
delivering TLRs from the ER to the endosome 95. All nucleic acid-sensing TLRs identified to 
date are Unc93b1-dependent, and are therefore located in the endosome. Moreover, 
trafficking of endosomal TLRs is affected by the ER chaperone gp96 96,97. The recognition of 
nucleic acids by endosomal TLRs may be aided by accessory proteins such as high mobility 
group box (HMGB). HMGB1, HMGB2, and HMGB3 bind to immunogenic RNA and DNA 
and thereby contribute to the activation of TLRs. HMGBs increase uptake of nucleic acids 
and function as universal nucleic acid labels 98. 
3.2.2.1 RNA recognition by TLR3 
TLR3 is expressed in macrophages and several subsets of DCs, but not in plasmacytoid DCs 
(pDCs) and monocytes 99–102. It is like all other nucleic acid-sensing TLRs located in the 
endosome. TLR3 is stimulated by double-stranded RNA (dsRNA) 37. The detection of RNA is 
sequence-independent and controlled by its secondary structure 37. TLR3 was the first TLR 
for which a crystal structure of the ligand-bound ectodomain was described 34. The dsRNA 
helix binds on two sides of the ectodomain, located at opposite ends of the TLR3 horseshoe 
103,40,34
. To be recognised, a critical length of 40 base pairs (bp) is needed 34,104. This enables 
binding of RNA at two TLR3 ectodomains, which stabilise and coordinate the dimer by 
intermolecular contact. The RNA binding sites of TLR3 function at pH levels below 6.5  
˗ a hallmark of the endosomal environment ˗ due to protonation of histidine residues 34,105,106. 
Thus, positively charged amino acids are able to bind negatively charged RNA. The critical 
length of 40 bp also prevents small cellular RNAs such as tRNA and miRNA from being 
sensed. Typically, TLR3-bound dsRNA occurs as an intermediate during viral replication. 
Furthermore,  mammalian RNA has been postulated to stimulate TLR3 in the presence of 
necrotic debris from neighbouring cells 107. The importance of recognition of viral infection 
by TLR3 is shown by the fact that immune responses to West Nile virus, murine 
cytomegalovirus, and Semliki forest virus have been found to be limited in TLR3-deficient 
mice 108,109,110. 
As a surrogate for natural dsRNA, many studies have used poly I:C, which is also able to 
stimulate RIG-I and MDA5 in the cytosol 111.    
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3.2.2.2 Recognition of RNA by TLR7 and TLR8 
TLR7 and TLR8 are two receptors that recognise single-stranded RNA (ssRNA) 33,32,31. 
Comparison of the sequences of all vertebrate TLRs indicated that TLR7 and TLR8 are most 
closely related; the next closely related is TLR9, then TLR3 112. 
In the murine system, the functional competence of TLR8 is unclear. The tlr8 gene is 
transcribed to mRNA, but TLR7-deficient mice are unable to respond to RNA in viral 
infections. It is therefore unclear whether the TLR8 receptor is functional. Furthermore,  
a five-amino acid region has been identified in all species with a functional TLR8 receptor 
and this region is missing in mice. Thus, the lack of this sequence may be responsible for the 
inactivity of the receptor 113. Another hypothesis is that TLR8 in mice might have an 
inhibitory function and modulate the immune response of other TLRs such as TLR7 or TLR9. 
Indeed, TLR8-deficient mice show higher expression of TLR7 and increased responses to 
TLR7 ligands in DCs, resulting in increased susceptibility to autoimmune diseases 114.  
In the human system, TLR7 is expressed exclusively in pDCs and B cells, and TLR8  
is expressed in macrophages and conventional DCs. In the murine system, TLR7 is  
more broadly expressed and can be found in macrophages and several DC subsets 99,100.  
The differential expression in the human system may explain the individual cytokine profiles 
of the two receptors 115. The overlapping expression in murine cells possibly neutralizes the 
effect of an inactive TLR8 116.  
TLR7 and TLR8 share specificity for ssRNAs and small synthetic molecules belonging to the 
imidazoquinoline group 33,30,32,31. In the human system, TLR7 is important for release of 
interferon-alpha (IFN-α) from pDCs and it preferentially recognises guanosine-/uridine-rich 
sequences 32,31,115. Adenosine-/uridine-rich sequences appear to be preferred by TLR8, which 
induces production of pro-inflammatory cytokines such as tumour necrosis factor (TNF) and 
IL12 115. The minimum length of RNA for efficient stimulation is debated, but 21 nucleotides 
appear to be sufficient 32,117,118. The preference for specific nucleotide sequences may be 
related to the RNA sequence composition of certain viruses, e.g. influenza A virus, human 
immunodeficiency virus, and vesicular stomatitis virus 33,32,31,119. Also, TLR7 plays an 
important role in sensing bacterial infections ˗ as reported for group B streptococci 116.  
In addition to Unc93b1, trafficking of TLR7 in pDCs is dependent on recruitment of AP-3 
and LC-3. They are responsible for localisation of the receptor in endosomal compartments 
specialised in type-I IFN induction 120,121. 
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As in all other TLRs, the ectodomains of TLR7 and TLR8 form a horseshoe structure.  
For TLR8, a crystal structure of the ectodomain with and without bound 3-diamino-furo[2,3-c] 
pyridine (a TLR8 ligand) has been published. Upon ligand binding, TLR8 is cleaved but the 
two halves remain associated and mediate dimerisation 122.   
TLR7 and TLR8 not only sense ssRNA; structural complexity is also important for 
recognition via TLR7. One kind of RNA that forms complex structures and that is recognised 
by TLR7 or TLR8 is tRNA. A tRNA molecule has one RNA strand with intramolecular base 
pairing and a complex three-dimensional structure. So ssRNA cannot be the only feature of 
RNA recognised by TLR7 and TLR8 123,124. 
Besides RNA, a number of small molecules called imidazoquinolines are capable of activating 
TLR7, TLR8, or both 30,17,125. Some of them are used in clinical therapeutics and they are 
often described as nucleoside analogues. The most important representatives of this group  
are Imiquimod and Resiquimod. Imiquimod (also known as R837) is a human and murine 
TLR7 agonist and it is used for treatment of genital warts and malignant skin tumours 126. 
Resiquimod (also known as R848) is recognised by TLR7 and TLR8 and is used as a drug for 
the treatment of skin lesions caused by viruses such as herpes simplex virus 127,128. It is also 
used as an adjuvant in vaccines 129. Both ssRNA oligoribonucleotides and imidazoquinolines 
are recognised by the ectodomains of TLR7 and TLR8. The small size of imidazoquinolines 
indicates that their mode of recognition by TLR7 and TLR8 differs from that of  
oligoribonucleotides 130. Studies in monocyte-derived DCs have suggested that there are 
differences in phosphorylation and transcriptional events activated by oligoribonucleotides 
and imidazoquinolines downstream of TLR8. In TLR7 and TLR8, overlapping and non-
overlapping binding sites for RNA and R848 have been found, indicating that 
imidazoquinolines require multiple or extended sites for binding to the receptors 130. The latter 
study suggested that the different classes of ligand (imidazoquinolines and oligoribonucleotides) 
can have different beneficial and harmful cellular effects 130.  
3.2.2.3 Recognition of RNA by TLR13 
TLR13 is an endosomal receptor that is only expressed in mice and rats. The tlr13 gene is 
located on the X chromosome, and its ligand was unknown until two groups independently 
reported in 2012 that bacterial RNA (bRNA) is the ligand for TLR13.  
Hidmark et al. found reduced cytokine production in DCs after bRNA stimulation when 
TLR13 was knocked down by siRNA 35. Furthermore, they showed activation of NFκB in 
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TLR13-transfected Chinese hamster ovary (CHO) cells ˗ by bRNA stimulation and addition 
of Streptococcus pyogenes ˗ in an RNA-dependent manner.  
Oldenburg et al. observed an activation of murine DCs by Staphylococcus aureus (S. aureus) 
in a TLR2-, TLR3-, TLR4-, TLR7-, and TLR9-independent manner 36. Furthermore, the 
activation was MyD88-dependant, suggesting involvement of a TLR. Further experiments 
with different DC subsets of several knock-out mice suggested a role of TLR13 in recognition 
of S. aureus. To find the exact ligand for TLR13, S. aureus preparations were treated 
enzymatically and the signal was abrogated after use of ssRNA-specific RNase. Fractionation 
of RNA identified 23S rRNA as the TLR13 ligand. The stimulation of TLR13 by 23S rRNA 
could be abrogated after growing S. aureus in the presence of erythromycin. In most cases, 
resistance to erythromycin is mediated by erythromycin resistance methylases (erm) that 
methylate a highly conserved adenosine at position 2058 (E. coli nomenclature), where the 
macrolides bind. This position is located in the sequence ‘CGGAAAGACC’, which has been 
identified as the stimulatory sequence of TLR13. Thus, it is a nucleic acid-sensing receptor 
with (as far as is known) strict sequence specificity. The sequence is highly conserved among 
gram-positive and gram-negative bacteria. Methylation or mutation of adenosine 2058 leads 
to a complete loss of TLR13 stimulatory capacity 36.  
Table 3-1: Different RNA-sensing receptors with their respective ligands and recognition principles 
Receptor Ligand(s) Recognition principle 
TLR3 dsRNA, poly I:C double-stranded, at least 40 bp 
TLR7 ssRNA, siRNA, tRNA, R837, R848 GU-rich RNA sequences 
TLR8 ssRNA, siRNA, tRNA (?), R848 AU-rich sequences  
TLR13 bRNA 
sequence-specific and modification-
dependent 
RIG-I viral RNA, poly I:C 
double-stranded, up to 2 kbp in length, 
5’-triphosphate 
MDA5 viral RNA, poly I:C double-stranded, at least 2 kbp 
NLRP3 bRNA unknown 
NOD2 ssRNA unknown 
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Of all the nucleic acid-sensing TLRs, TLR13 has the highest sequence specificity identified so 
far; only TLR9 has been shown to recognise DNA with similar sequence specificity for CpG 
motifs. TLR13 recognises a defined sequence in 23S rRNA, a ligand only found as non-self RNA. 
All the RNA-sensing receptors with their exact ligands and recognition principles are listed in 
Table 3-1. 
3.3 Discrimination of self RNA and foreign RNA 
3.3.1 The danger-associated molecular pattern theory 
The immune system is not only activated by PAMPs; it is also able to recognise so-called 
danger- or damage-associated molecular pattern (DAMPs). Since the 1950s, the theory of 
non-self recognition predominated. In the 1990s, Matzinger published the “danger theory”, 
discussing that non-self structures can be tolerated if they are not dangerous. Examples 
include commensal bacteria and the fetus 131–140. On the other hand, even self-compounds 
must be recognised if they are dangerous, for example during cellular stress or infection. 
Different host molecules have been identified that are capable of stimulating the immune 
system. In many cases, these molecules are secreted actively by infected or inflammatory 
cells, or they are released passively by necrotic cells. They are not released by apoptotic cells 
under physiological conditions.  
For example, heat shock proteins (HSPs) are a highly conserved protein family, and they play 
an important role as DAMPs 138,141,142. They are involved in folding, protection, and transport 
of proteins. HSPs can bind antigens and activate APCs. Other examples of DAMPs are uric 
acid, HMGB1, S100 proteins, and high concentrations of ATP 143–147.  
Nucleic acids are also a kind of DAMP, as they are released by dying cells and recognised by 
the immune system. Thus, in many cases the immune system has to distinguish between self 
RNA and non-self RNA. All nucleic acid-sensing receptors are able to sense mammalian RNA 
under pathophysiological conditions 148. If discrimination fails, and self RNA or even other 
molecules are recognised in the absence of danger or damage, autoinflammation and 
autoimmune diseases can occur.  
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3.3.2 Autoimmune diseases 
Autoimmune and auto-inflammatory diseases occur when the immune system attacks and 
destroys healthy tissue. It results from a misled immune activation. Nucleic acid-sensing 
TLRs especially ˗ such as TLR7, TLR8, and TLR9 ˗ have been reported to be involved in 
autoimmune diseases like systemic lupus erythematodes (SLE) and psoriasis 149–154. SLE can 
affect any part of the body. It attacks the body’s cells and tissues, leading to inflammation and 
tissue damage 155. Psoriasis is an immune-mediated skin disease characterised by red, scaly 
patches, papules, and plaques 156. The exact mechanisms that lead to autoimmune diseases are 
still unclear, but many of the components involved have been identified. IgG antibodies 
known as rheumatoid factors are produced by B cells after dual stimulation of antigen 
receptors and TLR9 157,158. When the uptake and the delivery of self DNA/chromatin 
complexes are enhanced, the TLR-mediated discrimination of self from foreign breaks down 
and self DNA induces stimulation. For SLE, it has been proposed that there is a TLR-
independent stage and a TLR-dependant stage. First, a TLR-independent uptake of debris 
derived from self cells by DCs takes place, followed by TLR-dependant recognition of the 
ingested nucleic acids. Both of these parts are driven by type-I interferons. Studies with 
ectopic expression of TLR9 at the cell surface instead of in endosomes, resulting in 
recognition of self DNA, have indicated the importance of spatial restriction 159. Similar 
results have been shown for RNA-containing immune complexes, triggering B cell receptors 
and TLR7 160. The uptake of nucleic acid/immunoglobulin complexes into pDCs is mediated 
by the low-affinity Fc receptor (FcγRIIA) and leads to TLR9 activation 154. The delivery of 
nucleic acids can also be mediated by the anti-microbial peptide LL37. It enhances the 
transport of aggregated DNA into early endosomes, leading to TLR9 stimulation. Thus, LL37 
converts self DNA to stimulatory DNA. This complex is resistant to DNase and plays an 
important role in pDC activation in psoriasis. It has been suggested that similar mechanisms 
are important for triggering of TLR7 with self RNA 161. Recognition of nuclei acids by TLRs 
may play a role in activation of pDCs and B cells, leading to production of autoantibodies 
against DNA and RNA ˗ as observed in SLE 162. Hence, the duplication of tlr7 promotes 
autoimmune diseases, pDC activation, enhanced type-I interferon production, and auto-
antibody formation in mice 163,164. Furthermore, TLR7 deficiency leads to reduced sensitivity 
to autoimmune diseases and to lower serum levels of autoantibodies 165,166.  
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TLR3 is associated with autoimmune liver damage and rheumatoid arthritis 167–169. Incubation 
of TLR3-expressing fibroblasts with necrotic synovial fluid cells from patients suffering from 
rheumatoid arthritis leads to increased chemokine and cytokine levels 170,171. 
Endosomal TLRs not only have a role in the direct recognition in autoimmunity. Studies with 
Unc93b1-deficient patients have shown defects in B cell tolerance, leading to accumulation of 
autoreactive B cells ˗ thus indicating that TLRs have a role in B cell maturation 172. 
These reports indicate that self-tolerance is important for nucleic acid-recognising TLRs and 
that discrimination of self from foreign is not specific to microbes, thus making spatial 
restriction by nucleic acid-sensing TLRs even more important.  
The spatial restriction prevents the conjunction of receptor and self-nucleic acid under 
physiological conditions 31,32,94,159. Furthermore, on the way to the endosomes, TLR9 is not 
functionally active. It has to be cleaved by a pH-dependent protease after endolysosome 
formation to be able to recognise RNA 173,174. This prevents recognition of cytosolic RNA 
during translocation 175. It has also been shown for TLR7 176 and may be true for other TLRs. 
3.3.3 RNA modifications 
Incorporation of modifications is an important tool to mark RNA as self, and thus prevent it from 
immune recognition. The importance of RNA modification depends on the TLR recognising the 
specific RNA. 
TLR3 recognises dsRNA with a minimum length of 40 bp. In an uninfected cell, only short, 
structured RNA such as tRNA and miRNA is present, but no RNA with a double-stranded 
motif of 40 bp. dsRNA of this minimum length is only present in virally infected cells, where 
the dsRNA is either derived from viral genomes or from replication intermediates 161. 
For TLR13, the discrimination is brought about by the fact that the receptor recognises a 
specific sequence that is only present in prokaryotic rRNA, but not in eukaryotic ones 36.   
TLR7 and TLR8 recognise ssRNA with a minimum length of 20 nucleotides. This length is 
found in mammalian cells, making other characteristics important for discrimination.  
While viral RNA uses the cellular machinery for replication of RNA, processing of bacterial 
RNA differs from that of mammalian RNA. Efficient identification of mammalian RNA is 
possible because of the cap structure of mRNA, polyadenylation, and post-transcriptionally 
introduced nucleotide modifications 161. Secretion of IL12 by human monocyte-derived DCs 
is enhanced by stimulation with bRNA and low upon stimulation with mammalian RNA 177. 
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In vitro-transcribed mRNA with no polyadenylation is again stimulatory, while stimulation 
after enzymatic 3’-polyadenylation abrogates cytokine secretion. This shows the important 
influence of polyadenylation in the identification of mammalian RNA. Also, post-
transcriptionally introduced nucleotide modifications play an important role in discrimination. 
They are abundant in eukaryotic RNAs and are much less common in bacterial and 
mitochondrial RNA 178. The lower frequency of modifications in mitochondrial RNA is due to 
the bacteria-like processing of RNA in the mitochondria as a result of their bacterial origin.  
In human rRNA, ten times more pseudouridines (Ψ) and 25 times more 2’O-methylated 
nucleosides are present than in bacterial rRNA. tRNA is the most commonly modified RNA; 
in mammals, up to 25% of all nucleosides in tRNA are modified 179. 
Modifications can also be found in the internal region of viral RNAs, for example in  
influenza virus, adenovirus, and herpes simplex virus. Often the viral mRNA is more 
frequently modified than the cellular mRNA, due to methyltransferases encoded by the virus.  
Karikó et al. observed in 2005 that there was a correlation between the number of modi-
fications and potency of stimulation 178. Their studies showed that the lower the number of 
modifications in the RNA, the higher was their immunostimulatory capacity. Further 
investigations identified different modifications that were able to abrogate stimulation of 
immune cells. In vitro-transcribed RNA with N6-methyladenosine (m6A), 5-methylcytidine 
(m5C), 5-methyluridine (m5U), 2-thiouridine (s2U), and pseudouridine (Ψ) circumvents 
recognition by TLR7 and TLR8 180,181. Thus, the amount and kinds of modifications appear to 
be important factors in discrimination between self RNA and foreign RNA.  
3.3.3.1 Naturally occurring modifications in tRNAs 
The RNA population of a cell consists of 80–90% rRNA and around 10% tRNA.  
This suggests that rRNA would possibly be important for recognition by immune receptors. 
However, rRNA is mostly present in ribosomes, and is therefore covered by proteins.  
Thus, tRNA is probably the most free RNA and is therefore the most likely to be recognised 
161
. As previously mentioned, in mammalian tRNA up to 25% of the nucleotides are modified 
and it is therefore the most abundantly modified RNA 179. The different tRNA modifications 
are linked to the different steps of protein synthesis 182. Unmodified tRNAs fail to produce 
proper proteins 182. The three loop regions are the most frequently modified parts of tRNA. 
The clover-leaf structure of tRNA is shown in Figure 3-2A, and the numbers indicate the 
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positions of modified nucleotides 182. Panel B shows the three-dimensional structure of tRNA. 
The D-arm and the T-arm interact resulting, in an L-shaped structure.    
  A                                                                  B 
 
Fig. 3-2: The structure of tRNA. (A) The clover-leaf structure of a model tRNA. The numbers show 
the positions of the nucleosides. (B) The L-shaped tRNA structure, in which the D- and T-arms 
interact by tertiary base pairing.182 
 
Methylations are important modifications in tRNAs; they are involved in stability and 
recognition. Methylation of tRNAs is mediated by different sequence- and position-specific 
tRNA methyltransferases. For example in E. coli, uracil-5-methyltransferase (trmA) is 
responsible for methylation of the uridine at position 54 (m5U54) of tRNA and guanosine-7-
methyltransferase (trmB) methylates the guanosine located at position 46 (m7G46) of  
tRNA 183,184. Gm18-2’O-methyltransferase (trmH) methylates the guanosine at position 18. 
This nucleoside at position 18 is highly conserved in the D-loop of tRNAs 185. It interacts with 
the conserved pseudouridine at position 55 in the T-loop. Together, they stabilise the  
L-shaped three-dimensional structure of tRNA 124. The structures of typical methylated 
nucleosides are shown in Figure 3-3 182.  
Most of the studies on modified RNAs have been performed with synthetic RNAs. Different 
modifications were incorporated into nucleosides with the same nucleobase; for example, all 
adenosines were methylated. In addition, the modifications were not tested in the natural environ-
ment ˗ i.e. sequence context, structure, and origin were not taken into account 178,180,181,186–188.  
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Fig. 3-3: Typical methylated nucleosides in tRNAs. The modifications are shown in red. The 
abbreviations for the modified nucleosides are shown in parentheses.182 
3.3.3.2 2’O-methylation of RNA 
2’O-methylation of ribose has been found as a modification in eukaryotic RNA, efficiently 
preventing TLR activation and resulting in an immunosilent RNA 189. Several studies have 
found a suppressive effect of 2’O-methylation on TLR7 activation in human and murine pDCs 
and monocytes 187,189–191; thus, 2’O-methylated RNA inhibits stimulation by simultaneously 
added stimulatory RNA. Thus, this RNA modification is immunoinhibitory. 2’O-methylation is 
much more abundant in eukaryotic RNA than in bacterial and mitochondrial RNA. 2’O-methyl-
ations have been found in mRNA, rRNA, tRNA, and several other non-coding RNAs 192–194.  
To test modifications as mechanisms of discrimination between RNAs in their natural context, 
Gehrig et al. isolated and analysed native tRNAs for their immunostimulatory capacity 123. 
Preparations of single tRNAs from E. coli (containing naturally occurring modifications) were 
compared with corresponding in vitro transcripts (without modifications) regarding their 
immune stimulation. Surprisingly, the tRNA for tyrosine (tRNATyr) lacked immune stimulation 
whereas the corresponding in vitro transcript was able to induce type-I interferon production 
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in human peripheral blood mononuclear cells (PBMCs). Thus, the observed difference could 
only have been due to a modification. Furthermore, 2’O-methylation at G18 was identified as 
being necessary and sufficient for abrogation of stimulation 123.  
3.4 Objectives of this work 
As outlined in the previous sections, microbial RNA has an important role as a target for 
detection of invading pathogens. Even so, under pathophysiological conditions self RNA can 
also be recognised, resulting in autoimmune and auto-inflammatory diseases. To distinguish 
between self and non-self RNA, naturally occurring RNA modifications can be used. 
Mammalian RNA ˗ especially tRNA ˗ is abundantly modified, whereas bacterial RNA 
contains fewer and different modifications. Interestingly, modifications introduced into 
mammalian RNA can silence or even inhibit recognition by and stimulation of the innate 
immune response. Most of the studies performed so far have analysed the effects of modificat-
ions in synthetic RNA oligonucleotides or in in vitro transcripts. The aim of this thesis was to 
determine the properties of one RNA modification in its natural context. The intention was  
to study the immunological effects of 2’O-methylation at position G18 of E. coli tRNATyr.  
The central hypothesis of the work for this thesis was that 2’O-methylation ˗ when 
incorporated into the natural sequence of a small oligoribonucleotide ˗ would be capable of 
suppressing immunostimulation. It was predicted that 2’O-methylated RNA would block the 
otherwise activated TLR7.  
We therefore investigated whether 2’O-methylated RNA can suppress immunostimulation by 
tRNA and by total RNA preparations from different bacterial species. If RNA preparations 
could be identified that (by themselves) did not show induction of immunostimulation, the 
preparations would be screened for additional modifications. To determine whether the 
inhibitory effect was specific for IFN-α production through TLR activation, the secretion of 
other cytokines was analysed. If any influence on other cytokines was observed, the relevant 
cell type and receptor would be identified. To determine the mechanism of inhibition,  
the signalling pathways of TLRs would have to be studied.  
Furthermore, the influence of the surrounding sequence next to the 2’O-methylated G18 for 
immunoinhibition needed to be studied. Thus, nucleobases in 2’O-methylated tRNAs would 
be mutated and the resulting tRNAs tested for immunostimulation. We believed that a specific 
“inhibitory” sequence motif might exist. 
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4 MATERIALS AND METHODS 
4.1 Materials 
4.1.1 Cells 
4.1.1.1 Mouse strains  
Primary murine cells were isolated from C57BL/6 mice purchased from Charles River 
Laboratories (Willmington, MA, USA) and bred under specific pathogen free (SPF) 
conditions. Breeding and monthly control of infection were performed according to the list of 
GV-SOLAS 1995. Killing and dissection were approved by the regional commission in 
Tübingen. Experiments were properly recorded and reported to Tübingen.  
4.1.1.2 Eukarytotic cells  
All eukaryotic cells were cultured at 37 °C, 5% CO2 in a humidified environment.  
The composition of the medium is described below. 
Murine BMDCs: Murine immune cells were generated from bone marrow cells to 
macrophages and dentritic cells. The bone marrow of tibiae and femur were used as described 
in 4.2.1.2 (Generation of murine primary bone marrow-derived dentritic cells). 
Human PBMCs: Human primary immune cells were isolated from blood of healthy donors 
as described in 4.2.1 (Isolation of human peripheral blood mononuclear cells).  
293XL-hTLR7-HA: HEK293XL cell line expressing HA-tagged human TLR7 gene, 
InvivoGen, San Diego, USA 
4.1.1.3 Media composition  
Inactivation of fetal calf serum (FCS): Sterile FCS was heat inactivated at 56 °C for 1 h to 
inactivate contained complement proteins. Afterwards it was decanted into aliquots and stored 
at -20 °C. 
Differentiation medium for BMDC: RPMI 1640 was supplemented with 10% (v/v) heat 
inactivated FCS, 1% (v/v) Penicillin/Streptomycin and 50 mM 2-Mercaptoethanol. 
Stimulation medium BMDC: RPMI 1640 supplemented with 10% (v/v) heat inactivated 
FCS 
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Stimulation medium PBMCs: RPMI supplemented with 10% (v/v) heat inactivated FCS 
Medium for HEK cells: DMEM supplemented with 10% (v/v) heat inactivated FCS,  
for HEK-TLR7HA further complemented with 10 µg/ml Blasticidin  
4.1.2 Instrumentation 
All instruments used through this study are listed in Table 4-1. 
Table 4-1: All instruments used in the study 
AutoMACS Miltenyi Biotech, Bergisch Gladbach, Germany 
Balance EW600-2M, Kern & Sohn GmbH, Balingen, Germany 
Blotting chamber Trans-blot® SD Semi-dry transfer cell, Bio-Rad, München 
Centrifuges Biofuge stratos, Multifuge 3S-R, Heraeus Instrumens, Hanau 
Biofuge fresco, Heraeus Instrumens, Hanau, Germany 
Biofuge pico, Heraeus Instrumens, Hanau, Germany 
Confocal microscope Leica TCS SP5, Leica Microsystems, Mannheim 
Counting chamber Neubauer 0.00025 mm2/0.1 mm, Brand GmbH, Schwerin  
Electrophoresis chamber Perfect Blue Mini ExM, Gelsize 14.4 x 10.2 cm, Peqlab, Erlangen 
Flow Cytometry BD FACS Canto (2-laser, 6 colour), BD Bioscience, Heidelberg 
Gel Documentation-System 
(Chemiluminescence detection) 
CN-3000.WL, Peqlab, Erlangen 
Heating block Thermomixer comfort, Eppendorf AG, Hamburg 
Incubator  BBD6226, Heraeus Instrumens, Hanau 
Magnetic shaking device IKA® RCT basic, IKA-Labortechnik, Staufen i. Br. 
Microtiterplate Photometer SUNRISE Absorbance Reader, Tecan, Salzburg, Austria 
Orbital Shaker Mini Rocker MR-1, Peqlab, Erlangen 
Rocky®3D, Labortechnik Fröbel GmbH, Lindau 
RS-24, Lab4You GmbH, Berlin 
pH-Meter Seven Easy, Mettler Toledo, Gießen 
Power Supply Power Supply 1000/500, BioRad, München 
Materials and Methods 
 
22 
 
Reflected light microscope Leica DMLS, Leica Microsystems GmbH, Wetzlar 
Safety cabinet Herasafe, Class II, Heraeus Instrumens, Hanau 
SDS-PAGE system perfectBlue™ Twi S, Peqlab, Erlangen 
Thermocycler Primus 25 advanced®, Peqlab, Erlagen 
Primus 96 advanced® gradient, Peqlab, Erlangen 
StepOnePlus Real-Time PCR System, Applied Biosysems, 
Darmstadt 
Spectrophotometer NanoDrop®ND-1000 Spectrophotometer, Peqlab, Erlangen 
UV platform ECX-26M, Peqlab, Erlangen 
Vortexer MS 1, IKA® Inc., Wilmington, USA 
4.1.3 Consumables  
All consumables used through the study are listed in Table 4-2. 
Table 4-2: List of all used consumables with suppliers 
Blot membrane, Nitrocellulose Immobilon-P Transfer, 0.45 µm pore size, Millipore Billerica, USA 
Blotting paper Whatman® GB003, Whatman GmbH, Dassel 
Caps Eppendorf-caps 0.5 ml, 1.5 ml, 2 ml; Eppendorf AG, Hamburg 
Cell culture bottles Cellstar® 25cm2 / 75 cm2 / 175 cm2, Greiner Bio-One GmbH, 
Frickenhausen 
Cell culture plates  
(flat bottom) 
Cellstar® 6- / 24- / 96- well plates, Greiner Bio-One GmbH, 
Frickenhausen 
Cell culture dishes 58 cm2; 145 cm2, Nunc GmbH & Co. KG, Wiesbaden 
Cell scraper Disposable Cell Scraper, Greiner Bio-One GmbH, Frickenhausen 
Cryo tubes Nunc GmbH & Co. KG, Wiesbaden 
Gloves Touch N Tuff Disposable Nitrile Gloves, Ansell, Brussels, Belgium  
ELISA plates 96 well half area plates, Greiner Bio-One GmbH, Frickenhausen 
FACS tubes BD Falcon™ 5 ml, BD Bioscience, Heidelberg 
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PCR plates MicroAmp Fast 96-well reaction plate (0.1 ml), Applied Bioscience, 
Darmstadt 
PCR tubes PP-PCR-tubes, Nat. 0.2 ml, Greiner Bio-One GmbH, Frickenhausen 
Petri dishes 145 x 20 mm, Greiner Bio-One GmbH, Frickenhausen 
Pipet tips TipOne, Star Lab, Hamburg 
Premium Line® Filter Tips, AHN Bioechnologie GmbH, 
Nordhausen  
Syringe BD Discardit II 27 G, 5 ml, 10 ml and 50 ml, BD Bioscience, 
Heidelberg 
Tubes Cellstar Tubes, 15 ml and 50 ml, Greiner Bio-One, Frickenhausen 
4.1.4 Chemicals and reagents 
All chemicals used for this study were purchased from Merck (Darmstadt) or Sigma-Aldrich 
(Taufkirchen) with a purity of “pro analysis”. All chemicals purchased from further companies 
listed in Table 4-3. 
Table 4-3: List of all used chemicals not provided by Merck or Sigma-Aldrich 
Aceton Riedel-de Haën AG, Seelze 
Acrylamid Roth, Karlsruhe 
Agarose ultra pure Gibco BRL, Life Technologies™, Eggenstein 
Aqua ad iniectabilia (10 ml) Braun, Melsungen 
Blasticidin  InvivoGen, Toulouse, France  
Dulbecco’s Modified agle Medium (DMEM, 1x) Biochrom AG, Berlin 
Ethanol Riedel-de Haën AG, Seelze 
FACSClean™ BD Bioscience, Heidelberg 
FACSFlow™ BD Bioscience, Heidelberg 
Fetale Calf Serum (FCS) Biowest, Nuaillé, France 
Isopropanol Riedel-de Haën AG, Seelze 
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Lipofectamin™2000 Invitrogen™, Karlsruhe 
Methanol Riedel-de Haën AG, Seelze 
Opti-MEM® I Reduced Serum Medium with 
GlutaMAX™ I  
Invitrogen™, Karlsruhe 
PBS (1x) for cell culture PAA Laboratories, Pasching, Austria 
Penicillin/Streptomycin solution (100 x) PAA Laboratories, Pasching, Austria 
Rotiphorese sequence gel system and sequence 
concentrate 
Roth, Karlsruhe 
RPMI 1640 Medium (1x) Biochrom AG, Berlin 
Sodiumchloride (NaCl) AppliChem GmbH, Darmstadt 
Sodiumdodecylsulfate (SDS) AppliChem GmbH, Darmstadt 
Sodiumfluoride (NaF) Roth, Karlsruhe 
TRIzol® Reagent Ambion, life techmologies, Darmstadt 
4.1.5 Buffers and solutions 
All buffers and solutions used in the study or listed with their composition in Table 4-4 to 
Table 4-7. 
Table 4-4: List of buffers and solutions used for western blot 
RIPA lysis buffer 50 mM Tris-HCL, pH 7.1; 1% (v/v) Igepal; 0.25% (v/v) sodium 
deoxycholat; 150 mM NaCl, 1mM EDTA 
Add fresh before use: 1 µg/ml of Aprotinin, Leupepin, Pepstatin;  
1 mM Na3VO4, NaF, PMSF 
Acrylamid stock solution 30% (v/v) acrylamide and bisacrylamid solved 29:1 
SDS running uffer 25 mM Tris-base, pH 8.3; 192 mM Glycin; 0.1% (w/v) SDS 
SDS sample buffer (4x) 200 mM Tris-HCl, pH 6.8; 20% (v/v) β-Mercaptoethanol;  
8% (w/v) SDS; 40% (v/v) Glycerol; 0.04% (w/v) Bromphenoleblue 
SDS blot buffer 25 mM Tris-base, pH 8.3; 192 mM Glycin; 20% Methanol 
SDS-stacking gel buffer (2x) 250 mM Tris-HCl; 0.2% (w/v) SDS; degassed before use 
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SDS separation gel buffer (3x) 1.123 M Tris-HCl, pH 8.8; 0.3% (w/v) SDS; degassed before used 
10 x TBS 100 mM Tris-HCl, pH 8.0; 1.5 M NaCl 
Blocking Buffer 1 x TBS; 0.1% (v/v) Tween20; 5% (w/v) BSA 
Wash Buffer 1 x TBS; 0.1% (v/v) Tween20 
 
Table 4-5: List of medium, buffers and solutions used for cell culture 
Trypan blue solution 2 mg/ml trypan blue in 1 x PBS 
Penicillin/Sreptomycin 10000 U/ml penicillin G; 10 mg/ml streptomycin; 
0.09% (w/v) NaCl 
RPMI 1640 medium PAA laboratories, Egelsbach 
DMEM PAA laboratories, Egelsbach 
 
Table 4-6: List of buffers and solutions used for ELISA 
Coating Buffer (pH 9.5) 0.1 M Sodiumcarbonate: 8.4 g NaHCO3, 3.6 g Na2CO3;  
adjust to pH 9.5; ad 1000 ml H2O 
Coating Buffer 0.2 M Sodiumcarbonate: 11.8 g Na2HPO4, 16.1 g NaH2PO4; 
adjust to pH 6.5; ad 1000 ml H2O 
Blocking Buffer 1 x PBS; 10% (v/v) FCS 
Wash Buffer 1 x PBS; 0.05% (v/v) Tween20 
Assay Buffer 1 x PBS; 0,5% (w/v) BSA; 0,05% (v/v) Tween20 
 
Table 4-7: List of buffers used for immunoprecipitation 
Lysis Buffer 136 mM NaCl, 20mM TrisHCl, 10% Glycerol, 2mM EDTA; adjust to pH7.4; 
1% Triton X100 
freshly added: 1 µg/ml of Aprotinin, Leupepin, Pepstatin; 1 mM Na3VO4, NaF, 
PMSF  
Washing Buffer 136 mM NaCl, 20mM TrisHCl, 10% Glycerol, 2mM EDTA; adjust to pH7.4; 
0.1% Triton X100 
freshly added: 1 µg/ml of Aprotinin, Leupepin, Pepstatin; 1 mM Na3VO4, NaF, 
PMSF 
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4.1.6 Biological reagents 
4.1.6.1 Primer 
All primers used through the study are listed in Table 4-9. 
Table 4-8: Primer sequences used for amplification transcripts 
Gene  Sequence 5’-3’ 
Product 
size 
(cDNA) 
Amplicon 
position 
h-β-Actin  fw AGAGCTACGAGCTGCCTGAC 
183 bp 
786-806 
 rv AGCACTGTGTTGGCGTACAG 989-969 
hIL1β fw GAGCAACAAGTGGTGTTCTCC 
140 bp 
668-688 
 rv TCCAGCTGTAGAGTGGGCTTA 807-787 
hTNF fw GCCCAGGCAGTCAGATCATCTTC 
181 bp 
395-417 
 rv TGAGGTACAGGCCCTCTGATGG 575-554 
hIL6 fw GGATTCAATGAGGAGACTTGC 
197 bp 
772-792 
 rv GTTGGGTCAGGGGTGGTTAT 968-949 
hIL12p40 fw GCGGAGCTGCTACACTCTC 
 
 
 rv CCATGACCTCCATGGGCAGAC  
unibac  fw AGAGTTTGATCMTGGCTCAG 
bacteria 
dependent 
27-88 (E.coli) 
16SrRNA rv CCGTCAATTCMTTTRAGTTT 926-907 (E.coli) 
4.1.6.2 Markers  
As marker for western blot analysis Page Ruler™ Plus Prestained Protein Ladder from 
Thermo Scientific, Karlsruhe was used. 
4.1.6.3 Antibodies 
All antibodies used for western blot analysis are listed in Table 4-9. The beads used for 
immunoprecipitation are listed in Table 4-10. 
Materials and Methods 
 
27 
 
Table 4-9: List of antibodies used for western blot analysis, all are from Cell Signaling, Frankfurt 
Antigen Species Phosphorylation sites Final dilution 
β-actin rabbit -- 1:1000 
p-p44/42 rabbit Tyr204/Tyr202 1:1000 
IκBα rabbit  1:1000 
p- IκBα rabbit Ser32 1:1000 
p-JNK/SAPK rabbit Thr183/Thr185 1:1000 
p-p38 rabbit Thr180/Thr182 1:1000 
HA rabbit -- 1:1000 
mouse IgG HRP-conjugated -- 1:4000 
rabbit IgG HRP-conjugated -- 1:4000 
 
Table 4-10: Substances used for immunoprecipitation 
detected tag  company 
HA agarose conjugated antibody Sigma Aldrich, Taufkirchen 
Biotin agarose conjugated streptavidin Thermo Scientific, Karlsruhe 
 
4.1.6.4 Stimulatory agents and used RNA strands  
All used RNA strands are listed in Table 4-11 to Table 4-13. All used TLR stimuli are listed 
in Table 4-14. The transfection agents used for transfection of RNA are listed in Table 4-15. 
 
Table 4-11: Sequences of RNA oligonucleotides used for experiments  
name sequence 
inhibitory RNA (inh. RNA) 5’ GGUGGGGUUCCCGAGCGmGCCAAAGGGAG 3’ 
control RNA (ctr. RNA) 5’ GGUGGGGUUCCCGAGCGGCCAAAGGGAG 3’ 
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Table 4-12: list of RNA oligonucleotides used to ligate tRNAs for motif studies 
name sequence  
fragment 1 5' GGUGGGGUUCCCGAGCGGCCAAAG 3' 
fragment 1-1 5' GGUGGGGUUCCCGAGCGmGCCAAAG 3' 
fragment 1-2 5' GGUGGGGUUCCCGAGCGGmCCAAAG 3' 
fragment 1-3 5' GGUGGGGUUCCCGAGCGGmGCAAAG 3' 
fragment 1-4 5' GGUGGGGUUCCCGAGCGmCCCAAAG 3' 
fragment 1-5 5' GGUGGGGUUCCCGAGCGmUCCAAAG 3' 
fragment 1-6 5' GGUGGGGUUCCCGAGCGmACCAAAG 3' 
fragment 1-7 5' GGUGGGGUUCCCGAGCCmGCCAAAG 3' 
fragment 1-8 5' GGUGGGGUUCCCGAGCUmGCCAAAG 3' 
fragment 1-9 5' GGUGGGGUUCCCGAGCAmGCCAAAG 3' 
 
 
fragment 2 5' GGAGCAGACUGUAAAUCUGCCGUCACAG 3' 
fragment 2-1 5' GGAGCAGACUGmUAAAUCUGCCGUCACAG 3' 
fragment 2-2 5' GGAGCAGACUGmAAAAUCUGCCGUCACAG 3' 
fragment 2-3 5' GGAGCAGACUGmGAAAUCUGCCGUCACAG 3' 
fragment 2-4 5' GGAGCAGACUGmCAAAUCUGCCGUCACAG 3' 
  
fragment 3 5' ACUUCGAAGGUUCGAAUCCUUCCCCCACCACCA 3' 
fragment 3-1 5' ACUUCGAAGGUUCGmAAUCCUUCCCCCACCACCA 3' 
fragment 3-2 5' ACUUCGAAGGUUCGmGAUCCUUCCCCCACCACCA 3' 
fragment 3-3 5' ACUUCGAAGGUUCGmUAUCCUUCCCCCACCACCA 3' 
fragment 3-4 5' ACUUCGAAGGUUCGmCAUCCUUCCCCCACCACCA 3' 
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Table 4-13: RNA oligonucleotides used for microscopy analysis, provided from IBA, Göttingen 
 unmodified RNA (5‘->3‘) 2’O-methylated RNA (5‘->3‘) 
s GCAAGCUGACCCUGAAGUUCAU GCAAGCUGACCCUGAAGUUCAU 
as (ATTO488)GAACUUCAGGGUCAGCUUGCCG (ATTO590)GAmAmCUUCAmGGGUCAmGCUUGCCG 
 
Table 4-14: List of used TLR stimuli 
stimulus stock 
concentration 
used 
concentration source 
CpG-ODN 1668 250 µM 1 µM InvivoGen, Toulouse, France 
CpG-ODN 2216 250 µM 1 µM InvivoGen, Toulouse, France 
R848 (resiquimod) 1 mg/ml 1 µg/ml InvivoGen, Toulouse, France 
Pam3CSK4 1 mg/ml 1 µg/ml 
InvivoGen, Toulouse, 
France 
Lipopolysaccharid (LPS) from 
Salmonella Minnesota (smooth form) 100 µg/ml 0.1 µg/ml 
provided by U. Seydel 
(Borstel) 
 
Table 4-15: transfection reagents used in the study 
Transfection reagent Company 
Dotap Carl Roth, Karlsruhe 
Lipofectamine 2000 life technologies, Darmstadt 
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4.1.7 Kits  
In Table 4-16 all kits used during the study are listed. 
Table 4-16: List of all used kits 
BD OptEIA™ ELISA Set (IL12p40, IL6, TNF, IL1β) BD Bioscience Pharminogen, Heidelberg 
CD14 MicroBeads human Miltenyi Biotech, Bergisch Gladbach 
eBioscience ELISA (hIFN-α) eBioscience, Frankfurt 
FastSYBR®Green PCR Master mix Applied Biosystems, Darmstadt 
High-capacity cDNA transcription kit Applied Biosystems, Darmstadt 
Immobilon™ Western Chemilumineszenz HRP 
Substrate 
Millipore, Schwalbach 
RNeasy® Mini Kit Qiagen, Venlo, Netherlands 
4.2 Methods 
4.2.1 Cell biology 
4.2.1.1 Cell culture of mammalian cells 
All cells were grown at 37 °C, 5% CO2 and 95% humidity in an incubator. Cell number of 
cell suspensions were determined by diluting cell suspension 1:10 in trypan blue solution 
staining exclusively dead cells. Cell numbers were count with Neubauer cell counting chamber. 
4.2.1.2 Generation of murine primary bone marrow-derived dendritic cells 
Bone marrow cells were prepared from 4- to 10-week old mice. Therefore the mice were 
sacrificed by CO2 asphyxia. Bone marrow was flushed out of tibiae and femurs with supple-
mented RPMI using a 27G syringe. The cells were singularized with a 20G syringe and count.  
For differentiation of dendritic cells 8 x 106 cells were seeded in a 145 cm2 tissue plate in 25 ml 
differentiation medium plus Granulocyte-macrophage colony-stimulating factor (GM-CSF). 
GM-CSF was derived from X-63 cells (supplied by M.Lutz, University Würzburg). They are 
cytoplastoma cells secreting murine GM-CSF. The amount was batch dependent. After 5 days 
the cells were fed by adding 25 ml differentiation medium and GM-CSF. At day 7 the non-
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adherent, immature dentritic cells were harvested by centrifugation (1300 rpm, 5 min). 
Afterwards the cells were count and seeded for experiments. 
4.2.1.3 Isolation of human peripheral blood mononuclear cells 
For isolation of human peripheral blood mononuclear cells (PBMCs) blood from healthy 
donors were taken with a syringe containing heparin. The heparized blood was mixed with  
1 x PBS in a ratio of 1:1 to 1:2 and added on top of Pancoll (d = 1,077 g/l) to separate the 
different compounds of the blood. After centrifugation (1800 rpm, 20 min, 4 °C, without 
brakes) the white ring between pancoll and serum was transferred in a new tube and filled up 
with PBS. The cells were washed by centrifugation (1300 rpm, 10 min, 4 °C) and resuspended 
in PBS. After a further centrifugation (1000 rpm, 15 min, 4 °C) to remove granulocytes, the 
cells were all put together and washed a last time with PBS. After centrifugation (1300 rpm, 
10 min, 4 °C) the cells were resuspended in RPMI medium supplemented with 10% FCS and 
count with a Neubauer cell counting chamber.   
4.2.1.4 Isolation of CD14+ cells 
CD14 positive monocytes were isolated by immunomagnetic cell separation which is based 
on magnetic antibody labeling (MACS-Microbeads). The labelled cells were separated by 
enrichment in a magnetic field and then eluted in a semi-automated manner from the column 
via AutoMACS device.  
To isolate CD14 positive monocytes, fresh isolated PBMCs were used with CD14 microbeads 
according manufacturer’s instructions. Thereby the CD14 positive cells were labeled and 
separated from the negative cells via AutoMACS Separator. The positive cells were eluted in 
the positive fraction by means of the program “possel”. This represents the enriched CD14+ 
monocytes. The cells eluted in the negative fraction were depleted of CD14+ cells. The cells 
were centrifuged (1300 rpm, 10 min, 4 °C), resuspend in RPMI supplemented with 10% FCS 
and used as indicated in stimulation. 
4.2.1.5 Cell stimulation 
Human primary freshly isolated cells were transfected reverse. Therefore the cells were added 
on top of the transfection mixture. For ELISA and RNA analysis, PBMCs and CD14- cells 
were adjust to 2 x 106 / ml, CD14+ cells were adjust to 1 x 106 / ml. For one duplicate, the 
transfection mixture was composed of 50 µl medium, stimulus and (3 µl/500 ng RNA) 
DOTAP (in case of RNA as stimulus). In case of inhibitory experiments, 500 ng/ml bRNA 
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and 1 µg/ml inhibitory or control RNA were used, corresponding to 108 nM. The mixture was 
incubated for 15 min at RT, before 170 µl medium were added. 100 µl were transferred in one 
well of a 96-well plate and 200 µl cells were added. The cells were incubated overnight if not 
indicated else in the experiment. 
For western blot analysis, 50 µl transfection mixture was incubated for 15 min at RT and 
transferred in a 24-well plate. 1 x 106 CD14+ cells were added in a total volume of 300 µl. 
The murine bone marrow derived dendritic cells were seeded in the wells minimal 2 h before 
transfection. The RNA was encapsulated in Lipofectamin (1 µl / µg RNA) for stimulation  
and incubated for 20 min at RT before adding to the cells. For ELISA 200 µl cell suspension  
(1 x 106 / ml) was seeded in a 96-well plate .The cells were incubated overnight. 
4.2.2 Confocal laser scanning microscopy 
For fluorescence microscopy the confocal laser scanning microscope Leica TCS SP5 
controlled by the Leica Application Suite Advanced Fluorescence (LAS AF) software was 
used. With the Argon (λ=488 nm) and DPSS 561 (λ=561 nm) laser the RNA labelled 
ATTO488 and ATTO590 were excited, respectively. Detectors were set corresponding to the 
emission spectra of the respective fluorescent dye (Table 4-17). 
To avoid cross-emission between different fluorescent channels, sequential image acquisition 
was used. Z-offset and photo multiplier were set manually to obtain specific signal without 
detection of unspecific signals in negative controls. 
Table 4-17: Properties of the fluorescent dyes used for microscopy 
fluorescent dye used laser λ excitation λ emission 
ATTO488 Argon 480 - 515 nm 500 - 600 nm 
ATTO590 DPSS561 575 - 610 nm 500 - 700 nm 
 
Live-cell imaging was performed in a specialised incubation chamber, adjusting temperature 
to 37 °C and control CO2 for 5% atmosphere. This chamber consists of Incubator S with 
Heating Insert P (PeCon, Erbach) controlled by Tempcontrol 37-2 digital (Leica) and CTI-
Controller 3200 (Leica).  
BMDCs were seeded in µ-Slides 8 well and incubated overnight. The live-cell imaging was 
started 1 h before transfection, to warm up Slides. The labelled RNAs (50 pmol each) were 
Materials and Methods 
 
33 
 
co-transfected with Lipofectamine2000. The imaging was started as soon as possible after 
transfection.  
Within one experiment, multiple visual fields were analysed in parallel using the “Mark and 
Find” mode of the LAS AF software in combination with a motorised high precision stage. 
The marked positions were recorded every minute over a time of 6 h. 
4.2.3 Immunoassays 
4.2.3.1 Enzyme-linked immunosorbant assay 
To quantify the amount of secreted cytokines, a sandwich ELISA was performed as indicated 
in the respective protocol of the manufacturers. Cell-free supernatants were diluted in PBS 
supplemented with 10% FCS (v/v) (blocking buffer) for measuring TNF, IL12p40, IL6 and 
IL1ß. For hIFN-α the supernatants were diluted in PBS supplemented with 0.5% BSA (w/v) 
and 0.05% Tween (v/v). All experiments were performed two or three times as indicated. The 
cytokines were detected by measuring the absorbance at 490 nm with 650 nm as reference in a 
photometer (SUNRISE Absorbance reader, Tecan, Salzburg, Austria). Cytokine concentrations 
were calculated using a standard dilution of the respective cytokines. In the end, concentrations 
were calculated with Magellan V 5.0 software (Tecan, Salzburg, Austria). Standard determination 
was performed according to the 4 parameter fit regression.   
4.2.3.2 Co-Immunoprecipitation 
To test the direct binding of RNA and TLR7, co-immunoprecipitations were performed. 
Therefore, HEK cells expressing TLR7-HA were transfected with RNA and beads were added 
to pull out one of the binding partners. The presence of the other was checked.  
HEKs growing in a 75 cm2 flask were resuspended in 5 ml OptiMEM and 1 ml was used per 
sample. The cells were transfected with 3 µg RNA (2 times 3 µg for co-transfection) for 1 h at 
RT. Afterwards the cells were centrifuged (7 min, 1300 rpm, 4 °C) and washed with 1 ml PBS. 
The cells were lysed with lysis buffer on ice for 10 min. The cell lysis was centrifuged again  
(7 min, 1300 rpm, 4 °C) to remove cell debris. In parallel, the agarose beads (10 µl / sample) 
were blocked with PBS 10% FCS for 1 h rotating at 4 °C. Afterwards, the beads were 
centrifuged (200 x g, 2 min, 4 °C) and washed with wash buffer. The beads were resuspended 
in 100 µl / sample wash buffer and added to the cell lysis. The mixture was incubated for 3 h 
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rotating at 4 °C. The samples were centrifuged (200 x g, 2 min, 4 °C) and washed three times 
with wash buffer.  
For analysing the amount of TLR7, meaning pulling out biotinylated RNA with streptavidin 
beads, 25 µl 2 x SDS was added to each sample and cooked 5 min at 95 °C. The samples were 
stored at -20 °C and used for western blot analysis (6% PAA-Gel) to detect the HA-TLR7.   
For analysing the amount of RNA pulled down with TLR7-HA using anti-HA beads, 1 ml 
Trizol was added to each sample. The samples were stored at -20 °C for short storage and 
used for RNA isolation followed by cDNA synthesis and qPCR analysis for 16SrRNA. 
4.2.4 Molecular biology 
4.2.4.1 RNA preparation from stimulated cells 
Total RNA was isolated from human PBMCs using peqGOLD Total RNA kit following 
manufacurer’s protocol. RNA isolation included DNase digestion. The isolated RNA was 
stored at -80 °C or directly used for cDNA preparation. 
4.2.4.2 cDNA synthesis 
cDNA synthesis was performed with High-Capacity cDNA transcription kit. Thereby the 
messenger RNA was transcribed to DNA using random primers. 10 µl of RNA were mixed 
with 10 µl mastermix including buffer, primers, RNase inhibitors, dNTPs, Reverse Transcriptase. 
The mixture was transcribed according to the manufacturer’s protocol. Afterwards, the cDNA 
(20 µl) was diluted with 40 µl H2O. 
4.2.4.3 Quantitative PCR 
For quantification of cDNA the cyanid fluorescent dye SybrGreen was used. It interferes with 
double stranded DNA and enables to monitor amplicon development. For the setup 2 µl 
cDNA was mixed with 18 µl maser mix, including fast SybrGreen mastermix, water and 
primers for the observing gene. The gene expression was measured in duplicates and was 
performed in a 96 well plate. The measurement was operated by StepOne Plus Real-Time 
PCR System. Thereby the program for amplification was performed as shown in Figure 4-1. 
Afterwards the dissociation curves for each amplicon were analysed to determine the melting 
point. Automatic detection of baseline and threshold values was used. To calculate the relative 
expression the determined Ct values were substrated from the Ct value of a reference gene, 
which is constitutively expressed (ß-actin), resulting in a ∆Ct for each target gene.  
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The relative expression (rE) was than calculated as rE = 1/(2∆Ct). As specificity controls no-
template and no RT (cDNA synthesis without adding reverse transcpritase) samples were 
included.   
 
Fig. 4-1: Running program for qRT-PCR 
4.2.4.4 Preparation of bacterial RNA  
For preparation of bacterial RNA (bRNA) the indicated bacteria were grown over night  
in media at 37 °C shaking. Only Bifidobacteria were grown under anaerobic conditions.  
For gram-negative bacteria and Staphylococcus aureus LB medium were used. For the other 
gram-positive bacteria BHI media were used.  
The culture was centrifuged for 10 min at 4000 x g and 4 °C. The supernatants were discarded 
and the pellets resuspend in 750 µl lysozyme (40 mg/ml) per 50 ml bacteria culture for 20 min 
at 37 °C to lyse the bacteria. Afterwards the samples were frozen at -80 °C and then 
resuspended in 5ml Trizol. After incubation at room temperature for 5 min, 1 ml Chloroform 
was added, vortexed and incubated for 2 min. The mixture was centrifuged for 60 min at  
4000 x g, 4 °C. Then the upper fraction was carefully transferred in a new tube, 1 ml per tube 
and mixed each with 830 µl Isopropanol. After incubation at room temperature for 10 min the 
tubes were centrifuged for 10 min at 12000 x g, 4 °C. After removing the supernatant, 1 ml 
75% ethanol was added in each tube and incubated for 5 min at room temperature.  
To sediment the RNA again, centrifugation at 7500 x g were performed for 5 min at 4 °C. 
The pellets were dried and resuspended in DEPC-H2O. The concentration was measured by 
means of the NanoDrop® ND-100 UV VIS Spectrophotometer. Aromatic rings of the RNA 
absorb the UV light at λ=260 nm.  
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To ensure a RNA preparation free of bacterial contaminants, the isolated RNA was additional 
isolated using RNeasy Mini Kit from Qiagen. Therefore 100 µg RNA per column was 
isolated according to the manufacturer’s protocol. The concentration was again measured and 
RNA was stored at -80 °C. 
4.2.4.5 Preparation of bacterial tRNA 
For preparation of isolated transfer RNA (tRNA) the whole bRNA preparation was separated 
by a denatured polyacrylamide gel electrophoresis and bands at the expected size were isolated. 
Therefore a 10% PAGE containing 0.8 M urea was prepared and run without samples for  
30 min at 200 V. Meanwhile the bRNA was mixed with loading dye. The pockets of the 
PAGE were rinsed with running buffer before the samples were load. The PAGE ran at 200 V 
for 2 h. The PAGE was removed from the apparatus and put on a paper for thin layer 
chromatography and delight with UV light. Than the tRNA bands were cut out, shred in small 
pieces and put with 0.3 M Na+-Acetat in a tube. After shaking with 550 rpm over night at room 
temperature to elute the RNA out of the gel, the supernatant were add on a column with a 0.45 µm 
pores and centrifuged at 2500 x g for 1 min. The flow through was transferred in a new tube 
and 2.5 V 100% cold ethanol were added and stored over night at -20 °C. To precipitate the 
RNA, the sample was centrifuged at 16000 x g for 90 min. Afterwards the pellet was dried 
and resuspended in RNase free H2O. The concentration was determined by NanoDrop®. 
4.2.4.6 Preparation of bacterial 16S rRNA 
To isolate 16S rRNA the whole RNA preparation of Staphylococcus aureus was used.  
The RNA was mixed with 2 x RNA loading dye and heated for 10 min at 70 °C before 
cooling down on ice for 3 min. The samples were put on a 1.5% low-melting agarose gel 
prepared with DEPC/TBE supplemented with SERVA Stain Clear G. The gel ran at 100 V. 
The bands were visualized by UV-light and the corresponding band cut out. After melting the 
agarose at 70 °C for 10 min, it was cooled down to 42 °C for 5 min. 1 U agarase was added 
per 100 mg agarose gel to digest the agarose and incubated at 42 °C for 30 min. Afterwards 
NH4-oAc was added to a final concentration of 2.5 M, incubated on ice for 3 min and 
centrifuged 10 min at 10000 rpm to separate the rest of the agarose gel from the RNA 
solution. The supernatant was transferred in a new tube and mixed well with 2/3 volume of 
phenol/chloroform. After incubation on ice for 10 min the mixture was centrifuged for 10 min 
at 13000 rpm, 4 °C. The upper aqueous phase was transferred in a new tube and mixed with  
1 volume of chloroform. After centrifugation (5 min, 13000 rpm, RT) the upper phase was 
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supplemented with 0.1 volume of 5 M NH4-oAc and the RNA was precipitated with 2 volumes 
of 100% ethanol at -80 °C for 30 min. During centrifugation (30 min, 13000 rpm, 4 °C) the 
RNA was pelleted and dried before re-suspended in DEPC-H2O at 37 °C for 5 min. The RNA 
solution was measured by NanoDrop®.  
4.2.4.7 Ligation of different modivariants of tRNATyr 
The ligation of the modivariants was performed by Steffen Kaiser (AG Helm), one of our 
cooperation partners in Mainz. 
Splinted ligation was performed by annealing three synthetic fragments of RNA (IBA 
Göttingen; 5′ fragment: GGUGGGGUUCCCGAGCGGCCAAAG; middle fragment: 
GGAGCAGACUGUAAAUCUGCCGUCACAG; 3′ fragment: ACUUCGAAGGUUCGAUC 
CUUCCCCCACCACCA), corresponding in sequence to unmodified E. coli tRNATyr or its 
modivariants/mutants onto a reverse complementary oligodeoxynucleotide (IBA Göttingen; 
TGGTGGTGGGGGAAGGATTCGAACCTTCGAAGTCTGTGACGGCAGATTTACAGTC
TGCTCCCTTTGGCCGCTCGGGAACCCCACC). Appropriate fragments (4 nmol) were  
5′-phosphorylated by incubating in KL buffer (50 mM Tris-HCl [pH 7.4], 10 mM MgCl2) 
supplemented with 5 mM ATP, 5 mM DTT, and 0.75 units/l T4 polynucleotide kinase (PNK, 
Fermentas) in a final volume of 150 µl in the thermomixer at 37 °C for 1 h. To the phosphory-
lation reaction mixture, an equimolar amount of the 5′ fragment and the DNA splint were 
added, as well as KL buffer, ATP (5 mM), and DTT (5 mM), leading to a final volume of 500 
µl and an 8 µM concentration of each fragment. The RNA fragments were hybridized to the 
DNA splint by heating to 75 °C in the thermomixer for 4 min and letting the reaction mixture 
cool down to room temperature for 15 min. Then, T4 DNA ligase (1.5 units/µl; Fermentas) 
and T4 RNA ligase 2 (22 ng/µl) were added, and the ligation was performed in the 
thermomixer at 16 °C overnight. Template DNA was removed by addition of 1.5 units/µl 
DNase I (Fermentas), followed by 1 h of incubation at 37 °C. The tRNAs were purified from 
ligation mixtures by denaturing PAGE, excised and eluted from the gel, and precipitated with 
ethanol. Concentrations were calculated from absorption at 254 nm, as determined on a 
Nanodrop ND-1000 spectrometer after resuspension in water. (Steffen Kaiser, University 
Mainz) 
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4.2.5 Biochemistry 
4.2.5.1 Preparation of protein lysates 
According to the experiments the cells were seeded in cell culture plates. For stimulation the 
cells were preincubated with medium containing less FCS before stimulated as mentioned in 
the experiments. After indicated timepoints, the plates were centrifuged (1 min, 13000 rpm) to 
attach the cells to bottom and the medium was carefully removed. The cells were washed with 
cold 1 x PBS. The cells were lysed in 100 – 150 µl freshly prepared RIPA lysis buffer 
supplemented with protease and phosphatase inhibitors and SDS for 10 min on ice. 
Afterwards the cell suspension was transferred in a tube and cooked for 5 min at 95 °C.  
The lysates were stored at -20 °C.  
4.2.5.2 SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was performed to 
separate proteins due to their molecular weight. Thereby SDS eliminates non-covalent 
bindings and charges the proteins negatively, whereby the amount of negative charge 
correlates with the length of the protein. Therefore the proteins can be separated by gel 
electrophoresis moving towards the positive electrode depending on their molecular weight.  
Up to 50 µl of each samples were loaded on a polyacrylamide gel, the percentage was 
dependent on the proteins of interest and the gel was run at constant voltage for 1.5 to 2 hours. 
A prestained protein marker was used as internal reference for size. Proteins from the gel 
were further analyzed by western blotting.    
4.2.5.3 Western blot analysis 
Proteins separated by SDS-PAGE were blotted on a nitrocellulose membrane (Millipore, 
Billerica, USA) by semidry blotting prodecure with 1.57 mA/cm2 membrane for 90 min using 
blocking buffer. To block unspecific binding sides, the membrane was incubated with 
blocking buffer for 1 h at RT on a vertical shaker. Afterwards, proteins were detected using a 
specific primary antibody diluted as indicated in blocking buffer and incubated over night at 4 °C 
on a vertical shaker. Membranes were washed three times with washing buffer before adding 
horseradish peroxidase (HRP)-conjugated secondary antibody diluted 1:4000 in blocking 
buffer for 1 h at room temperature. After three further wash steps with washing buffer bound 
antibodies were detected by chemiluminescence using enhanced luminol. Light emission was 
detected with a cooled CCD camera device. 
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4.2.6 Statistical analysis 
All experiments were performed at least two times and the number of experiments is stated in 
the legends. Means + SD are shown. Significant differences were evaluated by Student’s ttest 
in Microsoft Excel. Data were analyzed by means of GraphPad prism 4.03 program 
(GraphPad Software, San Diego California, USA). The stimulation curves for calculation of 
IC50 were calculated by R using the four-parameter Weibull functions195,196. p<0.05 (*), 
p<0.01 (**), p<0.001 (***) were considered significant. 
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5 RESULTS 
This work was an analysis of the role of the naturally occurring 2’O-methylation modification 
Gm18 in E.coli tRNATyr and its effect on innate immunity. Specifically, 2’O-methylation-
mediated inhibition of immune activation was studied in the work for this thesis. Underlying 
mechanisms and structural properties responsible for immunoinhibition by 2’O-methylated 
RNA were analysed.   
5.1 Inhibition by 2’O-methylated RNA 
5.1.1 Inhibition of IFN-α secretion by E. coli tRNATyr 
Access to pure native RNA species is limited. Thus, previous studies either used in vitro 
transcripts or short synthetic oligoribonucleotides to analyse the effects of specific RNA 
modifications on the immunostimulatory capacity. Moreover, most studies have been based 
on observations of self RNA and have not addressed the role of naturally occurring 
modifications in non-self RNAs. For example, 2’O-methylation has been shown to have 
suppressive effects on IFN-α secretion from pDCs via TLR7 activation when incorporated 
into synthetic RNAs, whereas its role in foreign RNA has not been analysed and discussed. 
This is of special interest because the modification also occurs in bacterial RNA 179,185,197,198. 
Therefore, in cooperation with AG Helm from the University of Mainz, we analysed the 
relevance of modifications in bacterial RNAs. Several native tRNAs and their corresponding 
in vitro transcripts (which therefore lacked the naturally occurring modifications) were tested 
for immunostimulation. It was found that native E. coli tRNATyr was not stimulatory while the 
corresponding transcript induced IFN-α 123. The difference in immunostimulation had to be 
due to RNA modifications, as this was the only difference between the native form and the 
transcript. Further experiments identified guanosine 2’O-methylation at position 18 (Gm18) 
as the modification responsible for inhibition of immunostimulation of plasmacytoid DCs 123. 
5.1.1.1 2’O-methylation in natural bacterial tRNAs 
In E. coli, the protein TrmH is responsible for the 2’O-methylation of guanosine at position 18 
(Gm18) in tRNA. It is the gene product of trmH and acts as a 2’-O-methyltransferase 185. 
Thirteen out of 45 tRNAs in E. coli carry a methylation at position G18, and trmH deficiency 
results in loss of this methylation 198. To determine the influence of 2’O-methylated tRNA
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the stimulation efficiency of bacterial RNA preparations, total tRNA preparations from wild-
type (wt) and a TrmH mutant E. coli (∆trmH) were isolated and used to transfect PBMCs. 
Induction of IFN-α is shown in Figure 5-1. While the wt tRNA induced only marginal 
amounts of IFN-α, the tRNA preparation from the TrmH mutant enhanced the production of 
IFN-α. This indicated an important effect of the 2’O-methylation at position G18 on immune 
stimulation. Surprisingly, stimulation with wt tRNA was very inefficient, even though 32 of 
45 tRNAs showed no methylation at position 18 and should therefore be stimulatory.  
The results suggested that the methylation modification mediated more than just 
immunosilencing.  
  
Fig. 5-1: Methyltransferase TrmH influences the 
stimulatory potential of E. coli tRNA. Human 
PBMCs were stimulated overnight with a whole tRNA 
preparation (500 ng/ml) derived from wild-type E. coli 
(wt) or a trmH deletion mutant of E.coli (∆trmH). 
IFN-α production was analysed by ELISA using cell-
free supernatants. The data are mean values (+ SD) of 
two independent experiments. 
 
We hypothesised that the 2’O-methylation not only prevents stimulatory activity but is also 
capable of inhibiting stimulation by unmodified tRNAs (by acting in a dominant inhibitory 
manner). To test this hypothesis, the native Gm18-containing E. coli tRNATyr was used in  
co-transfections in different ratios with native, stimulatory tRNAPhe lacking Gm18. tRNAPhe 
was previously shown to induce IFN-α in pDCs 123. The IFN-α production in this experiment 
is shown in Figure 5-2. At tRNAPhe:tRNATyr ratios of 1:1 and 1:2, stimulation was significantly 
reduced. The results suggested that tRNATyr is not only non-stimulatory but also has 
immunoinhibitory effects on TLR7-mediated IFN-α production. For a detailed analysis of the 
inhibition, a neutral non-stimulatory ˗ which was also uninhibitory ˗ was included. 
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Fig. 5-2: E. coli tRNATyr is capable of inhibiting 
simulation by tRNAPhe. E. coli tRNAPhe (500 ng/ml) 
with or without E. coli tRNATyr was used to transfect 
human PBMCs. The concentration of E. coli tRNAPhe 
was kept constant but it was combined with E. coli 
tRNATyr in the ratios indicated. The mixtures were 
encapsulated in DOTAP. The DOTAP volume was 
adjusted for the total amount of RNA. IFN-α levels 
were determined from cell-free supernatants by 
ELISA. The data represent the mean values (+ SD) 
from three independent donors. The data are 
normalised to the amount of IFN-α induced by 
tRNAPhe alone, to reduce donor-related variations. nt, 
not treated (negative control);  *p<0.05; **p<0.01    
5.1.1.2 Small portions of E.coli tRNATyr are sufficient to inhibit immunostimulation 
when incorporating 2’O-methylation  
Individual, fully modified native tRNAs are difficult to isolate. Likewise, preparation of a 
whole tRNA transcript bearing a single Gm18 modification is very time consuming 199.  
We therefore wanted to establish a tool to study the mechanisms of inhibition more easily.  
We wanted to determine whether a small fragment of a given tRNA containing the inhibitory 
Gm18 modification would be sufficient to inhibit stimulatory RNA.  
To test the hypothesis, we ordered a commercially synthesised oligoribonucleotide of 27 
nucleotides, of the same sequence as nucleotides 1–27 of tRNATyr and with incorporation of a 
2’O-methylation at position 18 (Gm18). The oligoribonucleotide was tested for immuno-
stimulation and for its ability to inhibit the stimulation of co-transfected RNA in a dominant 
manner. As control, the same fragment without any modification (“unmod”) was used  
(Figure 5-3). Both oligoribonucleotides (ORNs) failed to induce IFN-α when administered to 
PBMCs alone (grey bars). This was unexpected for the control oligoribonucleotide, yet it might 
indicate that a length exceeding 27 bps was necessary or that certain sequence motifs should 
be present to induce immunostimulation. After co-transfection with stimulatory bacterial 
RNA, IFN-α production was reduced by more than 90% with the methylated RNA 
oligonucleotide, while IFN-α secretion with the unmodified RNA oligonucleotide was 
reduced by less than 50% (black bars). We therefore concluded that the tRNA fragment with 
the methylation at position 18 was sufficient for abrogation of immunostimulation. The small 
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Gm18 was used for all future experiments and it was called inhibitory RNA. The unmodified 
version of the RNA fragment was used as the control.     
A B 
 
Fig. 5-3: A short fragment of the E. coli tRNATyr with 2’O-methylation at position G18 was 
found to be sufficient for the immunosilencing effects. (A) The structure of natural tRNATyr is 
shown on the right and the smaller fragment used for stimulation experiments is shown on the left. (B) 
Human PBMCs were stimulated with short oligoribonucleotides (as in A; 1 µg/ml) with (Gm18) or 
without (unmod) 2’O-methylation at position 18, and co-transfected overnight with (black bar) or 
without (grey bar) stimulatory RNA (500 ng/ml). Cell-free supernatants were assessed for IFN-α by 
ELISA. CpG-DNA (1 µM) and R848 (1 µg/ml) were used as positive controls to stimulate pDCs; nt, 
untreated negative control; The data are mean values (+ SD) of 3 pooled independent experiments, 
each done in duplicates. 
5.1.1.3 Immunostimulation of tRNA and total RNA prepared from different 
bacterial species 
Next, we wanted to know whether other RNA preparations from bacterial species other than 
E. coli would fail to induce IFN-α. This would help to identify other bacteria that use modificat-
ions as potential immune escape mechanisms and to find other immunosilencing or immuno-
inhibitory modifications. Also, we wanted to determine whether stimulatory tRNA preparations 
from different bacterial species could be inhibited by our inhibitory RNA preparation.  
tRNA preparations from a range of bacterial species were therefore isolated, including gram-
positive and gram-negative bacteria, pathogenic bacteria, and commensal bacteria. Human 
PBMCs were transfected with the tRNA preparations ˗ alone or together with inhibitory RNA 
˗ and the production of IFN-α was measured. As shown in Figure 5-4, all the tRNA 
preparations tested induced release of IFN-α in concentrations ranging from 1 ng/ml to  
2.5 ng/ml. Thus, no other immunosilencing tRNA preparations were identified.  
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After adding inhibitory RNA to the tRNA preparations, the amount of IFN-α secreted 
decreased for all bacterial species (Figure 5-4), indicating that the immunoinhibitory effect 
influenced the stimulation of tRNAs of a diverse set of bacterial species.   
 
 
 
It was found that the inhibitory RNA was able to suppress stimulation by a single tRNA and 
by total tRNA preparations from different bacterial species. In a preparation of total RNA, in 
addition to tRNA, mRNA, rRNA, and different small RNAs are present. To test whether these 
RNAs were also stimulatory and whether stimulation by total RNA extracts could also be 
inhibited, total RNA (bRNA) preparations from various bacterial strains were isolated and 
tested. The preparations were tested for their stimulatory capacity and for their ability to be 
inhibited by the methylated inhibitory RNA. All bRNA preparations were capable of inducing 
IFN-α production ranging from 1 ng/ml to 3 ng/ml (Figure 5-5). The concentration of RNA 
was the same as for tRNA preparations, and the stimulatory effects were also in the same 
range. Stimulation induced by bRNA preparations was reduced by over 90% after co-transfection 
with inhibitory RNA, except for bRNA of Salmonella sp and H. influenzae (Figure 5-5).  
Here, the stimulation decreased by only 50% and 70%, respectively.  
Unless otherwise indicated, in all the experiments that follow the total RNA preparation of  
S. aureus was used as total bRNA. 
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Fig. 5-4: tRNAs from different bacterial 
species induced IFN-α and could be inhibited 
by our inhibitory RNA. Whole tRNA
preparations (500 ng/ml) of Staphylococcus 
aureus, Streptococcus agalactiae, Bacillus 
subtilis, Bifidobacterium bifidum, Enterococcus 
faecalis, Helicobacter pylori and Campylobacter
jejuni were used alone (grey bars) or together 
with 1 µg/ml inhibitory RNA (inh; black bars) to 
transfect human PBMCs overnight. Cell-free 
supernatants were used to measure the 
production of IFN-α. R848 (1 µg/ml) was used 
as positive control. nt, untreated negative 
control; n.d., not detectable. The data are mean
values (+ SD) of 3 independent experiments. 
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Fig. 5-5: Total RNA preparations from different bacterial species were able to induce IFN-α and 
stimulation could be inhibited by inhibitory RNA. Whole RNA preparations (500 ng/ml) from 
different bacteria were used to transfect human PBMCs overnight, alone (grey bar) or together with 
(black bar) 1 µg/ml inhibitory RNA (inh). Production of IFN-α was measured by ELISA. CpG (1 µM) 
and R848 (1 µg/ml) were used as positive controls. nt, untreated negative control; n.d., not detectable. 
The data are mean values (+ SD) of 3 independent experiments, each done in duplicate. 
5.1.2 Inhibition of other pro-inflammatory cytokines 
Most of the data reported in the literature concerning 2’O-methylation of RNA and 
suppression of immunostimulation were derived from human PBMCs that were tested for 
IFN-α production. IFN-α in PBMCs is specific for pDC stimulation via TLR7 123,187,190. Other 
pro-inflammatory cytokines produced after activation of other cell types have not yet been 
investigated in detail. To determine the influence of other cell types in PBMC preparations, 
we measured the production of IL12p40 and TNF. PBMCs were stimulated with bRNA  
co-transfected with inhibitory RNA. As shown in Figure 5-6, bRNA was able to induce  
the secretion of pro-inflammatory cytokines IL12p40 and TNF in addition to IFN-α.  
Co-transfection with bRNA and inhibitory RNA led to a significant decrease in the production 
of IL12p40 and TNF. TNF and IL12p40 are not the characteristic cytokines produced by 
pDCs; these cells express TLR7 and TLR9 and they are known to mainly produce IFN-α and 
IL6 200.  Therefore, we concluded that bRNA is also capable of activating receptors other than 
TLR7, as TLR7 is exclusively expressed on pDCs and B cells. This other receptor has to 
recognise bRNA and is inhibited by inhibitory RNA. 
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It was observed above that tRNA and bRNA preparations from various bacterial species 
induce IFN-α production and that for all RNAs, IFN-α production could be inhibited by 
adding our inhibitory RNA. Next, we tested whether these particular RNA preparations could 
also induce pro-inflammatory cytokine production and whether this again could be inhibited.  
As shown in Figure 5-7, all the tRNA preparations tested led to production of IL12p40 and 
TNF (grey bars). Most tRNAs led to a cytokine production of between 500 and 1000 pg/ml  
˗ except for B. subtilis, which induced up to 3.5 ng/ml IL12p40 and 6 ng/ml TNF.  
Co-transfection with inhibitory RNA at a ratio of 1:2 greatly reduced the production of the 
cytokines induced by tRNA preparations from all the bacterial species tested (black bars). 
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Fig. 5-6: 2’O-methylated RNA is capable of 
abrogating the expression of different pro-
inflammatory cytokines. Human PBMCs were 
stimulated with 500 ng/ml bRNA preparation in co-
transfected with inhibitory RNA (inh) at a ratio of 1:2. 
Cell-free supernatants were analysed for production of 
(A) IFN-α, (B) IL12p40, and (C) TNF by ELISA. 
CpG (1 µM) and R848 (1 µg/ml) were used as positive 
controls; nt, untreated negative control; n.d., not 
detectable. The data are mean values (+ SD) of 3-5 
independent experiments; *p<0.05; ***p<0.001 
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Fig. 5-7: tRNA preparations from different bacterial species were found to be capable of 
inducing pro-inflammatory cytokines, and the induction could be inhibited by inhibitory RNA. 
tRNA preparations (500 ng/ml) from different bacteria were used to transfect human PBMCs 
overnight, alone (grey bars) or together with (black bars) 1 µg/ml inhibitory RNA (inh). Production of 
(A) IL12p40, and (B) TNF was measured in cell-free supernatants by ELISA. R848 (1 µg/ml) was 
used as positive control. nt, untreated negative control; n.d., not detectable. The data are mean values 
(+ SD) of 3 independent experiments, each done in duplicates. 
  
As the tRNA preparations caused induction of pro-inflammatory cytokines and the induction 
could be inhibited by inhibitory RNA, total bRNA preparations from different bacterial 
species were also tested. As illustrated in Figure 5-8, all the bRNA preparations tested were 
able to induce the cytokines analysed, but to somewhat different levels. While most of the 
bRNA preparations induced IL12p40 production to levels of 1 ng/ml or less, the bRNA of  
L. lactis induced production of up to 5 ng/ml IL12p40. For TNF, most of the bRNA 
preparations induced production of the cytokine at levels less than 5 ng/ml; only L. lactis 
induced production of around 12 ng/ml TNF. For all the bRNA preparations, they had been 
prepared by the same method and the same amount of RNA was used for transfection. On  
co-transfection with inhibitory RNA, the induction by most bRNAs decreased by at least 
90%. For the two Campylobacter species tested, no relevant decrease in secretion of IL12p40 
and TNF could be measured. This may have been due to contaminations with LPS. 
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Fig. 5-8: Total bRNA preparations from different bacterial species were found to be capable of 
inducing production of pro-inflammatory cytokines, and the induction could be inhibited by 
inhibitory RNA. Total bRNA preparations (500 ng/ml) of different bacteria were used to transfect 
human PBMCs overnight, alone (grey bars) or together with (black bars) 1 µg/ml inhibitory RNA 
(inh). Production of (A) IL12p40, and (B) TNF was measured in cell-free supernatants by ELISA. 
R848 (1 µg/ml) was used as positive control. nt, untreated negative control; n.d., not detectable; The 
data are mean values (+ SD) of 3 independent experiments. 
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5.1.2.1 Pro-inflammatory cytokines and IFN-α are secreted from different cell types 
In the previous section, we observed the induction of pro-inflammatory cytokines in response 
to bRNA. Because TLR7 is a nucleic acid-sensing receptor that recognises bRNA that is 
restricted to induction of type-I interferons and expression in pDCs, other cell types and 
receptors must recognise bRNA. 
In the literature, it has been observed that different nucleic acid receptors are expressed in 
different cell types: TLR7 and TLR9 are expressed mainly in pDCs and less in B cells, while 
TLR8 is mainly expressed in monocytes and only weakly in NK cells and T cells 102.  
We therefore investigated the relevance of monocytes for production of certain pro-
inflammatory cytokines in response to bRNA, as both IL12p40 and TNF are cytokines known 
to be secreted from monocytes. 
Monocytes were isolated by selection for CD14 expression and transfected with bRNA.  
In Figure 5-9, the cytokine expression was compared to that in CD14-negative cells and 
whole PBMCs. IFN-α production was found in PBMCs and CD14-negative cells, while 
secretion of TNF, IL12p40, and IL6 was found in PBMCs and monocytes. For all cell types 
and all tested cytokines, the stimulation by bRNA alone was inhibited by co-transfection with 
inhibitory RNA, but it was not reduced when bRNA was used in co-transfections with control 
RNA (Figure 5-9). For IL12p40, the cytokine induction by bRNA co-transfected with  
control RNA was not as high as for bRNA alone, but it was significantly higher than after 
transfection with bRNA along with inhibitory RNA. This observation might be due to 
competition between bRNA and control RNA for receptor binding, but the effect was not 
dominant, as the addition of inhibitory RNA reduced the signal even more. As monocytes are 
known to express high levels of TLR8, but not TLR7, it is possible that TLR8 in monocytes is 
responsible for production of pro-inflammatory cytokines in response to bRNA. Furthermore, 
cytokine induction could be inhibited by inhibitory RNA, raising the possibility that TLR8 
can also be inhibited by 2’O-methylated RNA. 
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Fig. 5-9: Pro-inflammatory cytokines are expressed by monocytes in response to stimulation by 
bRNA. Human PBMCs were used to isolate CD14-positive monocytes by MACS separation. PBMCs 
(2 × 106/ml) and CD14-positive (1 × 106/ml) and CD14-negative fractions (2 × 106/ml) were used for 
stimulation. bRNA (500 µg/ml) was used for co-transfection overnight with inhibitory or control 
RNA (each 1 µg/ml). Production of (A) IFN-α, (B) IL12p40, (C) TNF, and (D) IL6 was measured by 
ELISA. CpG (1 µM) and R848 (1 µg/ml) were used as positive controls; CD14-positive fraction: > 
90% CD14-positive, CD14-negative fraction: < 2% CD14-positive nt, untreated negative control; 
n.d., not detectable; The data are mean values (+ SD) of 3–6 independent experiments. 
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5.1.2.2 Inhibitory RNA does not inhibit immunostimulation by other TLR ligands 
As shown previously, inhibitory RNA was able to abrogate immunostimulation by different 
bacterial RNA species. This was observed in different cell types and for different cytokines. 
In the next step, we wanted to determine whether inhibition was specific for RNA recognition 
or whether other TLRs could also be inhibited, indicating an unspecific effect. Thus, different 
TLR ligands were used to stimulate PBMCs together with transfection by inhibitory RNA. 
CpG-DNA, R848, and Pam3CSK4 were used as ligands for TLR9, TLR7/8, and TLR1/2, 
respectively 30,201,202. R848 was selected because it activates the same receptor as bRNA. 
CpG-DNA activates TLR9, another nucleic acid-sensing TLR that is located in endosomes 
and specifically expressed in pDCs and B cells. Pam3CSK4 activates the dimer TLR1/2,  
a receptor for components of the cell wall of gram-positive bacteria that is located on the cell 
surface. In preliminary tests, the TLR ligands were titrated to find concentrations outside of 
the saturation range in order to make any inhibition apparent. As CpG-DNA activates TLR9, 
which is mainly expressed in pDCs, this stimulation was only tested for induction of IFN-α. 
Furthermore, Pam3CSK4 is not sensed by pDCs as they do not express any TLR1/2 dimer, 
resulting in no induction of IFN-α. Thus, this set-up was only analysed for secretion of 
IL12p40 and TNF. 
As shown in Figure 5-10, all TLR ligands were able to induce cytokines; only Pam3CSK4 
failed to induce production of significant amounts of IL12p40 in PBMCs. After addition of 
inhibitory RNA, the amounts of cytokines induced showed no significant differences ˗ even 
for R848. Only the induction by bRNA, as positive control, was reduced after addition of 
inhibitory RNA. As the cytokine production induced by bRNA is suppressed, but not that 
induced by R848, this finding indicates that there may be different recognition mechanisms 
for the two TLR7 ligands.   
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Fig. 5-10: Inhibitory RNA specifically interferes 
with bRNA-mediated stimulation but not with 
stimulation by other TLR ligands. Different TLR 
ligands were used to stimulate human PBMCs. 
Inhibitory RNA (inh; 1 µg/ml) was used for 
transfection together with each ligand to examine 
the degree of inhibition. PBMCs were incubated 
overnight and cell-free supernatants were analysed 
for production of (A) IFN-α, (B) IL12p40, and (C) 
TNF. R848 (TLR7/8; 1 µg/ml), bRNA (500 ng/ml), 
CpG (TLR9; 1µM), Pam3CSK4 (TLR1/2; 1 µg/ml). 
The data are mean values (+ SD) of 3 independent 
experiments; nt, untreated negative control; n.d., not 
detectable; n.s., not significant; *** p<0.001. 
 
5.1.2.3 2’O-methylated RNA suppress immunostimulation by bRNA more efficient 
than unmodified, nonstimulatory RNA 
In the previous sections, we have seen that inhibitory RNA can reduce the production of 
different cytokines induced by bacterial RNA. In the next step, we wanted to know whether 
the inhibitory RNA had the same efficiency for all cytokines and receptors. The inhibitory 
RNA was therefore titrated to a fixed concentration of bRNA to determine the concentration 
necessary for 50% inhibition (IC50). Titration curves with control RNA were performed in 
parallel as controls. The titration curves are shown in Figure 5-11. For all cytokines, secretion 
decreased after addition of inhibitory or control RNA. Yet, the inhibition was much more 
efficient when inhibitory RNA was added. The IC50 values were calculated for all curves 
using four-parameter Weibull function, and are shown in Table 5-1. The IC50 has been 
normalised to the cells and not to the receptor, as the experiments were performed in vitro and 
not with isolated receptor. In vitro, the binding of the RNA and the receptor is influenced by 
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different cellular properties such as uptake and transport, as well as cytokine production. 
Thus, the binding of the RNA to the receptor might result in different IC50 values for analysis 
with isolated receptors. The IC50 of the inhibitory RNA differed for the various cytokines.  
It was higher for IFN-α than for TNF. This might indicate a lower efficiency in inhibiting the 
IFN-α response. The IC50 for the control RNA was about 10 times higher for IFN-α and TNF 
than that for the inhibitory RNA. Yet, for TNF the curve fit was not optimal, as the curve for 
bRNA with control RNA did not fall to zero, showing that there was incomplete inhibition.  
 
A B 
            
C 
 
Fig. 5-11: Abrogation of immunostimulation by 
bRNA occurred at a lower ratio for inhibitory 
RNA. PBMCs were stimulated overnight with 1 µg/ml 
bRNA and different amounts of inhibitory (inh) or 
control (ctr) RNA. Cell-free supernatants were used to 
measure production of (A) IFN-α, (B) TNF, and (C) 
IL12p40 by ELISA. the data were normalised to 
cytokine production induced by bRNA alone to 
account for donor dependency. The x-axis shows the 
ratio of inhibitory or control RNA to bRNA. the data 
are average values from 2-6 independent donors. Curve 
fit and IC50 were calculated with R software using the 
four-parameter Weibull function. 
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Table 5-1: IC50 of the inhibitory RNA was less than the IC50 of control RNA. 
cytokine IC50 of inhibitory RNA  (ratio bRNA : inhibitory RNA) 
IC50 of control RNA 
(ratio bRNA : control RNA) 
hIFN-α 0.060 µg/ml 0.637 µg/ml 
hTNF 0.009 µg/ml 0.119 µg/ml 
hIL12p40 0.019 µg/ml 0.084 µg/ml 
 
5.1.3 Mechanisms of inhibition by 2’O-methylated RNA  
As inhibitory 2’O-methylated RNA was able to abrogate the activation of various cytokines 
by different RNA species, it is possible that different mechanisms are involved in this 
inhibitory effect. On the one hand, the inhibitory RNA could act as a competitive antagonist 
by binding to the same receptor. On the other hand, a further receptor could be present, 
sensing inhibitory RNA and then initiating an inhibitory pathway to repress positive signals of 
the RNA-sensing TLRs. The two hypothesises are depicted in Figure 5-12. To test which 
hypothesis might be correct, I investigated the repression of activation on different levels of 
the signalling pathway and analysed the binding of inhibitory RNA to TLR7.  
To determine which hypothesis was most correct, we investigated the repression of activation 
at different levels of the signalling pathway and analysed the binding of inhibitory RNA to 
TLR7. 
Fig. 5-12: Models for the mechanism of inhibition. 
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5.1.3.1 Inhibition of TLR activation by modified 2’O-methylated RNA is a rapid 
event 
Up to now, the repressive effect had always been observed after overnight incubation.  
To determine the level at which inhibition occurs, earlier time points and upstream effector 
events were examined.  
If the inhibitory RNA binds directly to the same receptor as the stimulatory RNA, inhibition 
should be observed at all time points. If, on the other hand, inhibitory RNA binds to another 
receptor, leading to a blocking of the RNA signal, an induction of the signalling might be 
observed at early time points. To investigate this, human PBMCs were co-transfected with 
bRNA and inhibitory or control RNA. At different time points (60 min, 120 min, 180 min, 
and 240 min), the cells were lysed and the expression of mRNA encoding different cytokines 
was analysed by qRT-PCR (Figure 5-13). Investigation of the mRNA levels was done 
because ELISA would not detect cytokine release at these early time points. 
For all the cytokines investigated, induction by R848 stimulation could be detected, starting 
early ˗ after 1 h. The induction increased further at later time points. For stimulation with 
bRNA, only slight induction was found after 1 h. For later time points, the cytokine induction 
increased further. For co-transfection with the inhibitory RNA, no or only slight induction 
could be measured for all time points. Co-transfection with bRNA and control RNA induced 
similar levels of cytokines as bRNA alone. For all cytokines, the expression after stimulation 
with R848 as positive control started earlier and reached higher levels (Figure 5-13).  
This could be because bRNA consisted of complex molecules and was packaged in 
liposomes, while R848 was a small molecule that did not need any liposomes to be taken up 
into the cell. Thus, the recognition for R848 might be faster than for bRNA. For all cytokines, 
the expression was significantly higher after stimulation with bRNA alone than after  
co-transfection with inhibitory RNA. For all cytokines, co-transfection with bRNA and 
control RNA led to similar expression levels as transfection with bRNA alone.  
Together, these data showed that inhibition by 2’O-methylated RNA occurred at early time 
points, indicating that a direct blocking of the signal might have taken place. 
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Fig. 5-13: Expression of cytokines decreased at early time-points after addition of inhibitory 
RNA. Human PBMCs were transfected with 1 µg/ml bRNA together with and without 2 µg/ml 
inhibitory (inh) or control (ctr) RNA. The cells were lysed at the indicated time points, RNA was 
isolated, and cDNA was synthesised. qPCR was performed for β-actin, TNF, IL1β, IL6, and IL12p40. 
The expression values of the cytokines were normalised to that of β-actin. The data are mean (+ SD) 
of three independent donors. R848 (1 µg/ml) was used as positive control. nt, untreated negative 
control;  *p<0.05; **p<0.01; ***p<0.001   
5.1.3.2 Inhibitory RNA blocks activation of downstream signalling 
Cytokine expression (according to the level of mRNA) was inhibited by 2’O-methylated RNA 
at all time points, indicating that the inhibition process started far upstream in the signalling 
cascade. Thus, in the next step I investigated whether the signalling cascade activated by 
bRNA was influenced when inhibitory RNA was added. I analysed the three main signalling 
pathways activated by TLR signalling, namely activation of MAPK, NFκB, and IRF. Activation 
of the MAPK pathway leads to phosphorylation of p42/44, p38, and JNK1/2. Activation of 
the NFκB pathway leads to phosphorylation and degradation of IκB-α, resulting in activation 
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of NFκB. Both pathways induce the expression of pro-inflammatory cytokines, i.e. of TNF 
and IL12p40. The third route that can be activated by TLR signalling leads to phosphorylation 
and enhanced expression of IRFs. Which IRF is activated will depend on the activated 
receptor. Activation of TLR7 leads to induction of IRF7, and TLR3 activation leads to IRF3 
induction. The IRF pathway results in a strong type-I interferon response.  
To study the effect of the inhibitory RNA on the different pathways, phosphorylation of 
different signalling intermediates was examined. Monocytes (CD14-positive cells) were 
therefore isolated from PBMCs and stimulated for 30 min. Monocytes were used as they are 
responsible for the production of pro-inflammatory cytokines, including TNF and IL12p40,  
in our set-up. By using one defined cell type, the background produced by unstimulated cells 
could be reduced. In Figure 5-14A, it can be seen that IκB-α was phosphorylated after 
stimulation with bRNA alone, bRNA plus control RNA, and after stimulation with R848. 
Only slight phosphorylation was observed after co-transfection with both bRNA and 
inhibitory RNA. Likewise, IκB-α was degraded upon transfection with bRNA alone, bRNA 
plus control RNA, and upon stimulation with R848, but not after stimulation with bRNA plus 
inhibitory RNA ˗ indicating that inhibitory RNA blocked the activation of the NFκB pathway 
by bRNA. 
Similar results were obtained for the MAPK pathway (Figure 5-14B). For p38 and p42/44, 
phosphorylation was observed after stimulation with bRNA alone, bRNA with control RNA, 
or R848. The untreated control and the cells co-transfected with bRNA plus inhibitory RNA 
showed no or only slight phosphorylation of MAPKs. Together, these data indicated that both 
pathways, the MAPK and the NFκB pathway, were inhibited by the inhibitory RNA.  
To study the influence of the inhibitory RNA on the IRF pathway, the induction of IRF7 
expression was measured by qRT-PCR analysis. IRF7 acts as transcription factor and is 
activated by phosphorylation downstream of TLR7 activation. Activation also leads to 
increased expression of IRF7. As shown in Figure 5-14C, expression of IRF7 increased after 
stimulation with R848 for 2 h and after transfection of RNA for 3 h, as observed for the 
expression of cytokines (Figure 5-13). After 3 h and 4 h, the induction of IRF7 by bRNA alone 
was significantly higher than induction by bRNA transfected together with inhibitory RNA. 
The co-transfection of bRNA together with control RNA was not significantly reduced.  
This result indicated that the IRF pathway was also inhibited. 
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A B 
                
C 
Fig. 5-14: Inhibitory RNA reduced signalling by 
bacterial RNA. (A and B) Human CD14-positive 
cells were transfected with 1 µg/ml bRNA in the 
presence or absence of 2 µg/ml inhibitory or control 
RNA. After 30 min, the cells were lysed and western 
blot analysis was performed. Antibodies against 
IκBα, p-IκBα (A), β-actin, p-p38, and p-p44/42 (B) 
were used to observe activation of the TLR 
downstream signalling pathways. One representative 
experiment of three is shown; R848 (1 µg/ml) was 
used as positive control. (C) Human PBMCs were 
transfected with bRNA  ˗  with or without inhibitory 
or control RNA. After the time-points indicated, the 
cells were lysed, RNA was isolated, and cDNA was 
synthesised. qPCR was performed for IRF7 and β-actin. The values of IRF7 were normalised to  
β-actin; R848 (1 µg/ml) was used as positive control. nt, untreated control; The data are mean values 
(+ SD) of 2 independent donors; *p<0.05; ***p<0.001  
 
5.1.3.3 Stimulatory and inhibitory RNA must be packaged together for inhibition 
Up to this point, all experiments had been performed with RNA that had been introduced in 
co-transfections, i.e. the stimulatory RNA and the inhibitory RNA were mixed before being 
encapsulated with DOTAP for transfection and endosomal delivery. This procedure would 
have ensured uptake of both RNAs in the same cell and the same endosome. We wanted to 
determine whether this co-localisation was necessary and whether pre-stimulation of the cells 
with the stimulatory bRNA or blocking with inhibitory RNA would alter the efficiency of 
inhibition of cytokine production. Thus, both RNAs were encapsulated separately and used to 
transfect PBMCs at different time points. After incubation overnight, the release of cytokines 
was measured. The results are shown in Figure 5-15.  
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For IFN-α production (Figure 5-15A), a slight inhibition could be observed with all 
approaches. Interestingly, approaches in which the inhibitory RNA was added after the 
stimulatory RNA showed less IFN-α production (down to 20% of that for bRNA alone) than 
the approaches involving pre-treatment with the inhibitory RNA (down to 60% of that for 
bRNA alone). No approach was as efficient as co-transfection with both RNAs. Even 
transfection with stimulatory and inhibitory RNA at the same time, but individually 
encapsulated, reduced the stimulation down to 70% of that for bRNA alone.  
For IL6 production (Figure 5-15B), the results were not as clear as for IFN-α. First, there 
were greater standard deviations. For one donor, the IL6 production was four times increased 
for pre-transfection with inhibitory RNA compared to transfection with bRNA alone. For the 
other donors, the cytokine production was decreased down to 20% of the stimulation by 
bRNA alone for pre-treatment with inhibitory RNA. For pre-stimulation with stimulatory 
bRNA, only one donor showed reduced IL6 production (down to 20%); the others had 
increased cytokine release compared to stimulatory RNA alone. Co-transfection reduced the 
IL6 production completely for all donors. 
Ninety minutes of pre-treatment of the cells with inhibitory RNA resulted in five times more 
TNF than was induced by the bRNA alone (Figure 5-15C). Transfection with both separately 
encapsulated RNAs at the same time reduced the TNF production to 45% of bRNA that for 
bRNA alone. Addition of inhibitory RNA to bRNA resulted in a decrease in TNF production 
down to 50% of that for bRNA alone. Only pre-stimulation by bRNA for 2 h enhanced TNF 
production to 120% of that for bRNA alone. Again, co-transfection was the most efficient and 
least variable method of inhibition of cytokine production.  
In summary, pre-treatment of the cells with inhibitory RNA reduced the amount of inhibition, 
and in some cases the cytokine production was even enhanced. The most efficient inhibition 
was observed after co-transfection with both RNAs. Yet, addition of inhibitory RNA up to 2 h 
after stimulation reduced the amount of cytokine secretion even when the bacterial RNA was 
delivered separately. 
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A B 
C 
 
Fig. 5-15: Stimulatory and inhibitory RNA 
must be packaged together for inhibition. 
Human PBMCs were stimulated with 1µg/ml 
bRNA and 2 µg/ml inhibitory RNA at different 
time points. Thus, the RNAs were encapsulated 
separately in lipoplexes for transfection and 
endosomal delivery. For “bRNA + inh.” the 
RNAs were encapsulated together. After 
overnight incubation, the cell-free supernatants 
were used in ELISA to measure production of 
(A) IFN-α, (B) IL6, and (C) TNF. Each symbol 
(circles, squares, and triangles) represents mean 
of one donor normalised to bRNA alone. 
5.1.4 Inhibitory RNA acts as an antagonist for TLR7 signalling 
The above results indicated that modified RNA inhibits early events in TLR7 signalling. 
Thus, 2’O-methylated RNA might bind directly to the receptor stimulated by bRNA, block it, 
and thereby prevent activation. To test this hypothesis, HEK293 cells stably expressing  
HA-tagged TLR7 were transfected with 16S rRNA of S. aureus in the absence or presence of 
inhibitory RNA. The cells were lysed and the RNA was pulled down by isolating the TLR7 
protein with α-HA beads. RNA bound to the protein was isolated with TRIzol and cDNA 
synthesis was performed. The cDNA was analysed by qPCR using 16S rDNA primers from a 
conserved region. The CT values are plotted in Figure 5-16. They indicate the amount of  
16S rRNA bound to the receptor, whereby a lower CT indicates more RNA bound. The results 
suggested that 16S rRNA bound to TLR7. After addition of inhibitory RNA to the cells,  
the amount of 16S rDNA detected decreased by 1 cycle, indicating that the amount of  
16S rRNA was reduced by 50% as the DNA is doubled in each cycle. This indicated that the 
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inhibitory RNA might have displaced the 16S rRNA from the receptor. 16S rDNA could also 
be detected in the background control. This might be due to contamination of the reagents 
used. Compared to the samples of bRNA plus inhibitory RNA, only one-sixteenth of the  
16S rDNA was detected in the background control.  
 
To verify these first results, the experiment was switched around and the amount of receptor 
bound to RNA was analysed. Thus, HEK293 cells stably expressing HA-tagged TLR7 (131 kDa) 
were transfected with a short biotinylated and stimulatory siRNA. The siRNA was used 
because it was known to stimulate immune activation and could be bought with a biotin tag. 
The stimulatory capacity of the siRNA is shown in Figure 5-17A, where it was used to 
transfect PBMCs. The ability of 2’O-methylated RNA to inhibit the stimulation by the siRNA 
is also shown. The biotinylated RNA was isolated with streptavidin beads and co-
immunoprecipitation of TLR7 was analysed by western blot analysis using an HA antibody. 
The co-immunoprecipitation of TLR7-HA with biotinylated RNA is shown in Figure 5-17B. 
For HEK cells transfected with biotinylated RNA alone, two bands were detected. The same 
bands were observed for co-transfection with biotinylated RNA and control RNA, but not for 
co-transfection with inhibitory RNA. Both bands resulted from proteins smaller than the 
expected size of TLR7-HA (131 kDa). For TLR7-HA pulled down with anti-HA beads,  
one band of the expected size was detected. The proteins detected in the two bands after  
co-immunoprecipitation might be smaller due to cleavage of TLR7 during processing in the 
endosome or by activation (see Discussion). Yet, it was not formally proven whether the 
bands represented TLR7, and for this purpose an anti-TLR7 antibody should be used.  
background 16S rRNA 16S rRNA + inh. RNA
20
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Fig. 5-16: 16S rRNA may bind directly to TLR7 and can be 
displaced by 2’O-methylated, inhibitory RNA. HEK-
TLR7HA cells were transfected with 3 µg/ml 16S rRNA from 
S. aureus with or without inhibitory RNA (3 µg/ml) for 1 h. The 
cells were lysed and anti-HA agarose beads were added for 3 h.
Afterwards, the samples were washed and RNA was isolated 
with TRIzol. The 16S rRNA was detected with qRT-PCR using 
16SrDNA primers from conserved regions. One representative 
experiment of three is shown. 
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Fig. 5-17: TLR7 is replaced from the stimulatory RNA by the 2’O-methylated RNA. (A) 500 µM 
siRNA was used alone or together with 500 µM 2’O-methylated RNA to transfect PBMCs. After 
overnight incubation, cell-free supernatants were analysed for IFN-α content. R848 (1 µg/ml) was 
used as positive control. nt, untreated negative control; The data are mean values (+ SD) of 
4 independent experiments; ***p<0.001. (B) HEK-TLR7HA cells were transfected with 3 µg/ml 
siRNA used in panel A tagged with biotin and with or without 3 µg/ml unlabelled inhibitory (inh.) or 
control (ctr.) RNA. The cells were lysed and streptavidin or anti-HA agarose beads were added for 
3 h. The samples were washed and western blot analysis was performed using an anti-HA antibody. 
The data are from one experiment representative of five. 
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Next, we wanted to be sure that the inhibitory RNA not only blocks the binding of stimulatory 
RNA to the receptor, but binds directly to it. The approaches tested are shown in Figure 5-18A. 
In a first approach, biotinylated tRNATyr with or without methylation at position 18 was used 
for co-immunoprecipitation of TLR7-HA. The protein bound to the pulled-down tRNATyr was 
analysed by western blotting. For the methylated tRNA and for the unmodified tRNA, slight 
bands could be seen, indicating that both tRNAs were able to bind to the receptor (Figure 5-18B, 
“1”, “2”). Again, the band detected was not of the expected size. Thus, it could not be 
excluded that the band detected was an unspecific signal. In a second approach, cells were  
co-transfected with equal amounts of biotinylated modified tRNATyr and unlabelled 
unmodified tRNATyr. After pull-down of biotinylated RNA with streptavidin beads, a strong 
signal was detected for TLR7 in the co-immunoprecipitation, comparable to that observed for 
the biotinylated tRNATyr alone (Figure 5-18B, “3”). By contrast, when cells were co-transfected 
with unmodified biotinylated tRNATyr plus 2’O-methylated unlabelled tRNATyr, only a weak 
band for TLR7 could be detected in the co-immunoprecipitation (Figure 5-16B, “4”).  
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Fig. 5-18: 2’O-methylated RNA may bind directly to TLR7 and displace unmodified RNA. (A) 
Schematic illustration of lysates used foe co-immunoprecipitation in panel B. (B) HEK-TLR7HA 
cells were transfected with 3 µg/ml tRNA tagged with biotin, with or without 3 µg/ml tRNA without 
any tag. The cells were lysed and streptavidin beads were added for 3 h. The samples were washed 
and western blot analysis was performed using an anti-HA antibody. The numbers below the blot 
indicate the tRNA composition illustrated in panel A. 
The assays used were somewhat limited in quality and interpretation. The biotinylated RNA had 
to reach the endosome and bind to the receptor. Thus, the amount of TLR7 in the endosomes 
was limited. Moreover, we could not be certain that all biotinylated RNAs were introduced by 
transfection and located in the endosome when the cells were lysed. Not all liposomes 
containing RNA are taken up at the same time, and RNA in the endosomes would be degraded 
after a time. Thus, a time point had to be used at which the amount of receptor-bound RNA 
was maximal. This is perhaps why only weak bands could be detected.  
Together, these preliminary data indicate that unmethylated and methylated tRNATyr might 
compete for binding at the same receptor and that methylated tRNATyr binds to TLR7 with a 
higher affinity than its unmethylated counterpart. 
A B 
 
5.1.5 Distribution of 2’O-methylated and unmodified RNA in immune cells 
In the experiments performed thus far, the stimulatory RNA was mostly introduced by  
co-transfection with the inhibitory or control RNA. The results indicated that modified and 
unmodified RNA compete for receptor binding. Thus, both kinds of RNA probably had to be 
taken up in the same endosomes where TLR7 or TLR8 were expressed. To study this in more 
detail, murine bone-marrow derived DCs (BMDCs) were co-transfected with two double-
stranded synthetic RNA oligonucleotides. They were selected because double-stranded RNA 
is more stable than single-stranded, and by modifying only one strand the location of the 
modified strand and the unmodified strand in the same compartment would be ensured.  
One of the strands was 2’O-methylated at all adenosine residues and linked to the fluorescent 
dye ATTO590. The other oligonucleotide was the corresponding unmodified RNA 
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oligonucleotide linked to ATTO488. The sequences of the RNA oligonucleotides are shown in 
Table 5-2. The distribution of the RNAs was observed by live-cell imaging using a confocal 
laser scanning microscope over a period of six hours. Pictures at different positions were taken 
at one-minute intervals.  
A: t = 8 min B: t = 3 h 8 min 
  
C: t = 6 h 8 min  
  
In Figure 5-19, three pictures from different time points are shown. For all time points 
observed, co-localisation of the different labelled RNAs ˗ indicated by a yellow signal ˗ in small 
dot-like structures was seen. This indicated a co-localisation in liposomes and endosomes. Also, 
the efficiency of delivery was calculated using the microscopy data. It was determined to be 
between 60% and 70% in the different positions and experiments.  
Fig. 5-19: 2’O-methylated and unmodified 
RNA are co-located in liposomes and 
endosomes. BMDCs were co-transfected with 2 
different double-stranded RNA oligonucleotides 
and the distribution was observed by live-cell 
imaging using a confocal laser scanning 
microscope over a period of more than six hours. 
One RNA oligonucleotide was 2’O-methylated at 
all adenosines in one strand and linked to 
ATTO590 (red fluorescent signal). The other 
RNA oligonucleotide was unmodified and linked 
to ATTO488 (green fluorescent signal). Three 
timepoints are shown. 
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Table 5-2: Sequences of RNA oligonucleotides used in localisation studies 
 
unmodified RNA (5´→3´) 2’O-methylated RNA (5´→3´) 
s GCAAGCUGACCCUGAAGUUCAU GCAAGCUGACCCUGAAGUUCAU 
as (ATTO488)GAACUUCAGGGUCAGCUUGCCG (ATTO590)GAmAmCUUCAmGGGUCAmGCUUGCCG 
 
In the images, release of the fluorescent-labelled RNA into the cytosol was apparent and 
different distribution of 2’O-methylated RNA and the unmodified RNA was observed 
thereafter. This release was observed periodically in all transfected cells. The distribution in 
the cells was the same each time: the ATTO488-labelled unmodified RNA was mainly 
located in the cytoplasm, while the 2’O-methylated RNA labelled with ATTO590 was 
distributed in the nucleus.  
   
   
           
Fig. 5-20: ATTO488-labelled unmodifed RNA oligonucleotides appeared to be co-located with 
ATTO590-labelled 2’O-methylated RNA oligonucleotides in liposomes and endosomes. BMDCs 
were co-transfected with 2 different double-stranded RNA oligonucleotides and the distribution was 
observed by live-cell imaging using a confocal laser scanning microscope over a period of six hours. 
One RNA oligonucleotide was 2’O-methylated at all adenosines in one strand and linked to 
ATTO590 (red fluorescent signal). The other RNA oligonucleotide was unmodified and linked to 
ATTO488 (green fluorescent signal). 
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To investigate the distribution in more detail, a representative part of the picture was enlarged 
and a sequence over one hour is shown in Figure 5-20. Right at the beginning of the 
observation, the distribution of the fluorescent-labelled RNA showed dot-like structures 
within the cells and outside of them, consistent with localisation of RNA in liposomes and 
endosomes after uptake into the cells. The distribution appeared similar for both fluorescent 
signals. Then, fluorescent-labelled RNA was released into the cytoplasm, resulting in distinct 
locations of the different RNAs. The red fluorescent signal appeared to localise more in the 
nucleus whereas the green fluorescence was detected more in the cytoplasm. Still, yellow 
fluorescent dots-like structures could be seen inside the cell and outside, indicating vesicles 
containing red and green fluorescent signals. After a while, the fluorescent signals for both 
RNAs vanished, and recurred later, still co-located in vesicles. During the whole six-hour 
period, this cycle of dot-like structures and fluorescent RNA released into the cytoplasm with 
different distributions for both RNAs was consistently observed. 
These observations could indicate that both RNAs are co-located in liposomes and endosomes 
but that they are released from the endosomes and distributed differently inside the cell.  
The unmodified RNA oligonucleotide was located more in the cytoplasm while the  
2’O-methylated RNA oligonucleotide was distributed more in the nucleus. To verify this 
observation, the experiments were done with the dyes exchanged. The unmodified RNA 
oligonucleotide was linked to ATTO488 and the 2’O-methylated RNA oligonucleotide was 
linked to ATTO590. Again the RNAs were used for co-transfection and the cells were 
observed by live-cell imaging using a confocal laser scanning microscope over a period of six 
hours. For the transfected cells, a representative part of one position was enlarged and it is 
shown over a period of 45 min in Figure 5-21. Again, dot-like structures could be seen, 
indicating co-localisation of the 2’O-methylated and unmethylated RNA in endosomes and 
liposomes. Again, the release from the endosomes was apparent, followed by different 
localisation inside the cell. The red fluorescent signal was mainly detected in the nucleus and 
the green fluorescent signal was mainly detected in the cytoplasm. In this set of experiments, 
the green fluorescent signal seemed to give a stronger signal than the earlier one. 
The data therefore indicated that the different distributions of the 2’O-methylated and 
unmodified RNAs observed by microscopy were independent of the methylation. Instead,  
the distribution was due to the different fluorescent dyes used in the experiments. 
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Fig. 5-21: The distributions of fluorescent labelled RNA oligonucleotides inside the cell were a 
result of fluorescent dyes used, not the modification. BMDCs were co-transfected with 2 different 
double-stranded RNA oligonucleotides and the distributions were determined by live-cell imaging 
using a confocal laser scanning microscope over a period of six hours. One RNA oligonucleotide was 
2’O-methylated at all adenosines in one strand and linked to ATTO488 (green fluorescent signal). 
The other RNA oligonucleotide was unmodified and linked to ATTO590 (red fluorescent signal). 
5.1.6 Inhibitory RNA in the murine system 
In the human immune system, bRNA stimulates TLR7 in pDCs to induce IFN-α production 
and eventually TLR8 in monocytes. In the murine system, TLR8 has been reported to be  
non-functional. Furthermore, it has been shown that TLR13 is responsible for recognition of 
bRNA in mice 35,36.  
As there are differences between the murine and human systems, we wanted to check whether 
the inhibitory RNA identified is able to abrogate stimulation by RNA in murine cells. 
Therefore, murine BMDCs were transfected with bRNA and inhibitory RNA, and production 
of different cytokines was analysed (Figure 5-22A and B). Secretion of TNF and IL12p40 was 
induced by bRNA. The effect of the 2’O-methylated RNA used in the co-transfections  
was not consistent. While in some experiments the induction of cytokine secretion was 
inhibited, in other experiments only a slight decrease or even no difference was observed 
(Figure 5-22A and B, respectively). Interestingly, in the experiments showing a slight 
decrease in cytokine secretion with inhibitory RNA, bRNA and positive controls induced 
higher secretion of cytokine compared to the other experiments. The different results may 
have been due to differences in cell differentiation from using different batches of 
differentiation medium. 
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Further analysis indicated a similar mechanism for the partially observed inhibition as for the 
human system; the inhibitory effect could be observed at the mRNA level and at the level of 
MAPK activation. However, the MAPK signal was not entirely abolished, possibly explaining 
the less efficient inhibition in some experiments. The differences might be due to the expression 
levels of TLR13. In the cells in which only a slight inhibition could be found, the expression 
of TLR7 might be reduced while the TLR13 expression was enhanced. In this way, the 
activation of TLR13 would be responsible for the production of cytokines and the activation 
would not be inhibited by the 2’O-methylated RNA added. 
Again, we investigated whether the effects of other TLR ligands could be inhibited. Inhibition 
of different TLR ligands would indicate an effect specific for TLRs and exclude a specific 
effect of RNA stimulation. To test this, different TLR ligands were used to transfect cells along 
with inhibitory RNA and the cells were examined for cytokine production. The results for 
TNF and IL12p40 are shown in Figure 5-23. In previous experiments, the different ligands 
were titrated to avoid concentrations in the range of saturation. For polyI:C, a TLR3 ligand, 
no induction was observed for both cytokines ˗ even for stimulation without any inhibitory 
RNA. Both R848 ˗ a TLR7 ligand ˗ and Pam3CSK4 (TLR1/2) led to induction of TNF and 
IL12p40, which was not significantly affected by co-administration of the inhibitory RNA. 
 
 
Fig. 5-22: 2’O-methylated RNA is unable to inhibit cytokine secretion consistently in murine 
immune cells. Murine BMDCs were transfected with 1 µg/ml bRNA with or without 2 µg/ml 
inhibitory RNA. After incubation overnight, cell-free supernatants were analysed for production of 
(A) TNF and (B) IL12p40. Each symbol represents the mean of one experiment. The experiments 
were performed using different batches of differentiation medium. nt, untreated negative control.
R848 (1 µg/ml) and CpG-DNA (1 µM) were used as positive controls. 
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5.1.7 Summary of part 5.1 
So far, we had found that RNA containing a 2’O-methyl modification at position G18  
˗ as occurs naturally in E. coli tRNATyr ˗ could inhibit the production of IFN-α induced through 
TLR7 activation in human pDCs by stimulatory RNA. We also found that 2’O-methylated RNA 
is also capable of inhibiting TNF, IL12p40, and IL6 production by human monocytes in 
response to stimulatory RNA. Inhibition occurred at the level of mRNA expression without 
any time lag. Early events in signal transduction were inhibited. Both the stimulatory RNA and 
the inhibitory RNA appeared to bind directly to the receptor, and this binding was competitive. 
Inhibitory RNA displaced the stimulatory RNA from the receptor, and probably had higher 
affinity. The specificity of inhibitory RNA for inhibition of stimulation by bRNA was proven 
by lack of inhibition of CpG-DNA (TLR9) and Pam3CSK4 (TLR1/2). Interestingly, stimulation 
of TLR7 and TLR8 by R848 could also not be inhibited by 2’O-methylated RNA, indicating 
that there may have been a different mode of ligand recognition for R848 than for bRNA.  
Murine BMDCs showed only minor inhibitory effects of 2’O-methylated RNA, indicating 
that the mouse-specific TLR13 may have an important role that is not affected by the presence 
of 2’O-methylated RNA. 
Fig. 5-23: Inhibitory RNA is unable to inhibit induction of cytokine production by synthetic 
TLR ligands. BMDCs were stimulated with different TLR ligands mixed with (dotted bars) or 
without (grey bars) 2 µg/ml inhibitory RNA (inh. RNA) before encapsulation in lipoplexes. The cells 
were incubated overnight and cell-free supernatants were examined for (A) TNF and (B) IL12p40
production, using ELISA. R848 (TLR7): 20 ng/ml; pIC (TLR3): 1 µg/ml; Pam3CSK4(TLR1/2): 
1 µg/ml. nt, untreated negative control; The data are mean values (+ SD) of duplicates in one 
experiment representative of three. 
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5.2 Identification of a 2’O-methylated dinucleotide motif responsible 
for tRNA silencing 
It is assumed that TLR7 recognises RNA depending on a certain order of nucleotides 118, but 
the exact stimulatory motif is still poorly defined. It was discovered very recently that post-
transcriptional modifications play an important role in this context. In native tRNATyr, there is 
a methylation of the 2’-hydroxyl function of the ribose of the guanosine at position 18 198. 
This guanosine is located in the structural core of the L-shaped tRNA. The primary function 
of the modification may be structural stabilisation of the region 193,203,204. The role of this 
modification in immune stimulation may have evolved as a secondary feature. To better under-
stand the function of the sequence for TLR7 recognition, we produced different modivariants 
of tRNATyr that differed regarding the nucleoside that was methylated, the next nucleoside 
downstream, and the position of the methylation within the tRNA sequence. Modivariants of a 
tRNA have the same sequence as the native tRNA, and only one or two positions are modified 
or mutated. They are produced by ligation of three different parts of the tRNA using a DNA 
template 199. The different modivariants were tested for their ability to induce cytokine 
expression in human PBMCs. The production of different cytokines due to transfection with 
the different RNAs was measured by ELISA.  
5.2.1 The influence of three-dimensional structure on immunosilencing 
As the methylation of tRNATyr at position 18 is important for structural stability of the region 124, 
we studied the influence of the three-dimensional structure on immunosilencing. The native 
tRNATyr forms hydrogen bonds between G18 and G19 ˗ with C56 and U55, respectively.  
The methylation of the ribose at position 18 might influence this structure, thereby leading to 
immunosilencing. To investigate this possibility, the nucleobases 55 and 56 in the T-loop of 
tRNATyr were mutated to guanosines to abrogate the building of hydrogen bridges and thereby 
destroy the three-dimensional structure of the tRNA (Figure 5-24). Mutations in the T-loop 
resulted in an unaltered, silent tRNA. Changing of the cytidine at position 56 to guanosine 
gave the same weak level of cytokine secretion as the native sequence with methylation at 
position 18. No difference in IFN-α induction was observed when position 55 was also 
mutated to guanosine. We therefore concluded that the three-dimensional structure had no 
influence on the immunosilencing efficiency of the methylated tRNATyr.  
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Fig. 5-24: The three-dimensional 
structure has no influence on 
immunosilencing capacity of tRNA. 
Different modivariants of tRNATyr 
were synthesised and PBMCs were 
transfected with each at 500 ng/ml. 
Cell supernatants were assayed for 
IFN-α production by ELISA. The 
native tRNATyr contained all 
modification that naturally occurr in 
the tRNA, while all other tRNAs 
contained only Gm18. The numbers 
under the bases indicate the position in 
the tRNA. The data are mean values (+ 
SD) from 2 independent donors, each 
measured in triplicate and normalised 
to the unmodified in vitro transcript of tRNATyr to avoid donor-related variation. nt, untreated 
negative control. 
5.2.2 Methylation of guanosine alone is not sufficient for immunosilencing  
Native tRNATyr has a ribose-methylated guanosine at position 18. This is followed by another 
guanosine (GmG). To study position-dependent effects of this inhibitory modification, we 
shifted the methylation downstream by one nucleotide ˗ to position 19. The molecular weight 
and the sequence of the tRNA were the same, and only the position of the methyl group 
differed by 5 Å. The resulting tRNA was tested for induction of cytokine expression.  
The positions of the 2’O-methylations in the three-dimensional structure and the sequence are 
shown in Figure 5-25A and Figure 5-25B, respectively.  
Analysis of Figure 5-25C–F shows that the immunosilencing ability of the tRNA was 
negatively affected in this new construct for all cytokines tested. While the modification at the 
original position (Gm18) prevented induction of cytokine production, moving of the 
methylation to position 19 resulted in high levels of cytokine secretion. The exact degree of 
induction depended on the cytokine and the donor, but in all cases the induction was 
significant. For IFN-α and TNF production, most donors showed only slight induction and 
only one or two donors showed an increase comparable to that with the transcript alone. For 
IL6, most of the donors led to an increase up to 15 times higher than that for the transcript.   
Analysis of the motif around the modification showed that the former motif GmG was 
changed by shifting to methylation to position 19, resulting in GmC. Interestingly, the 
immunosilencing effect was completely recovered by changing the nucleobase at position 20 
to guanosine. The resulting motif GmG was now the same as for methylation at position 18, 
indicating that the sequence motif played an important role in immunosilencing.  
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Fig. 5-25: translocation of the methylated motif by one nucleotide downstream affects 
immunosilencing. (A) Location of the nucleotides 18 and 19 in the three-dimensional model of 
tRNATyr (adapted from AG Helm, Mainz). (B) Location of nucleotides 18 (X), 19 (Y), and 20 (Z) in 
the sequence of tRNATyr (adapted from AG Helm, Mainz). (C-F) PBMCs of two to six donors were 
activated by transfection with the indicated tRNA (500 ng/ml) overnight. The methylation at position 
18 (GmGC) was translocated to position 19 (GGmC) and the nucleobase at position 20 was changed 
from cytidine to guanosine (GGmG). Cell-free supernatants were used to measure production of (C) 
IFN-α, (D) IL6, (E) TNF, and (F) IL12p40 by ELISA. Data were normalised to the unmodified tRNA 
transcript to avoid donor dependency. Each dot in the figure represents the mean of duplicates from 
one donor, and blue lines represent the mean of all donors. nt, untreated control; *p<0.05; ***p<0.001  
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To examine the influence of all nucleobases on the immunosilencing effect, other mutants of 
the tRNA were synthesised. These tRNAs included the ribose methylation at position 18, 
while the identity of the nucleoside at position 19 varied. The location of the transposed base 
in the three-dimensional structure and in the sequence are shown in Figure 5-26A and  
Figure 5-26B, respectively. The cytokine induction capacity of the different variants is shown 
in Figure 5-26C–F. For all cytokines, the native sequence GmG failed to cause 
immunostimulation. Changing of the guanosine at position 19 to adenosine did not alter 
expression of any cytokine. Changing of the guanosine at position 19 to a uridine led to a 
significant increase in expression of all cytokines except for IL12p40. For IFN-α and IL6, the 
strongest increase in cytokine secretion was induced by a tRNA with a cytidine at position 19. 
For TNF, the production was also significantly higher than with the native sequence GmG, 
but less than with GmU. For IL12p40 induction, no significant differences were observed for 
all sequence motifs tested. The sequence motifs with their corresponding cytokine induction 
are summarised in Table 5-3. Interestingly, the sequence motif GmC was able to induce high 
amounts of TNF when G19 was 2’O-methylated, while no TNF induction was observed with 
the 2’O-methylated G18 followed by a cytidine. For the other cytokines, no differences 
between the two methylation sites were observed. This indicated that the nucleobase 
following the methylated position had a greater influence on the immunosilencing effect on 
IFN-α and IL6 production, while for silencing of TNF and IL12p40 the nucleobase appeared 
to have no effect. This might be due to different specificities of TLR7 and TLR8. 
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Fig. 5-26: The nucleobase following at position 19 influences the immunosilencing effect. (A) 
Location of nucleotides 18 and 19 in the three-dimensional model of tRNATyr (adapted from AG 
Helm, Mainz). (B) Location of nucleotides 18 (Gm) and 19 (Y) in sequence of tRNATyr (adapted from 
AG Helm, Mainz). (C-F) PBMCs from two to six donors were activated by transfection with the 
indicated tRNA (500 ng/ml) overnight. The different tRNAs had a 2’O-methylation at position 18 and 
were mutated at the next position to different nucleobases. Cell-free supernatants were used to 
measure production of (C) IFN-α, (D) IL6, (E) TNF, and (F) IL12p40 by ELISA. Data were 
normalised to the unmodified tRNA transcript to avoid donor dependency. Each dot in the figure 
represents the mean of duplicates from one donor, and the blue lines represent the mean of all donors. 
nt, untreated negative control; *p<0.05; **p<0.01; ***p<0.001   
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Taken together, the data indicated that the ribose methylation at position 18 alone was not 
sufficient to abrogate induction of IFN-α and IL6. The immunosilencing effect was highly 
efficient when a purine (adenosine or guanosine) was present at position +1. The presence of 
a pyrimidine (uridine or cytidine) had an adverse effect on the silencing. This was less strong 
for uridine but stronger for cytidine. In the natural context, the sequence at position 18 of 
tRNAs is highly conserved. Especially in species expressing TrmH, the enzyme responsible 
for Gm18 in tRNAs, the identified sequence context around G18 is widely spread among 
different species. This highlights the relevance of our findings, as they correspond to the usual 
situation in tRNAs 194.   
Table 5-3: Stimulation of cytokine expression by different tRNAs containing diverse sequence 
motifs around the 2’O-methylation. 
 IFN-α IL6 TNF IL12p40 
GG +++ +++ +++ +++ 
GmG - - - - 
GmA + - - - 
GmU ++ + + - 
GmC +++ ++ -/+++ - 
 
5.2.3 Permutation of the 2’O-methylated base 
In the next step, we studied the influence of the nucleobase itself at the methylated ribose. 
Again, different variants of the tRNA ˗ differing at the methylated position 18 ˗ were 
synthesised. The location of the changed nucleobase is shown in Figure 5-27A and B.  
The induction of the different cytokines is shown in Figure 5-27C–F. As expected, the native 
sequence (GmG) showed no induction of any cytokine. Mutation of guanosine at position 18 
to adenosine again showed no cytokine induction; nor did mutation of position 18 to uridine. 
However, a cytidine at the methylated position 18 led to induction of all cytokines.  
This induction was significant ˗ compared to the native nucleobase Gm ˗ for all cytokines 
except of IL12p40. Here, great donor variation prevented any exact conclusion. 
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Fig. 5-27: Cytidine with a methylated ribose lacks immunosilencing activity. (A) Location of 
nucleotides 18 and 19 in the three-dimensional model of tRNATyr (adapted from AG Helm, Mainz). 
(B) Locationof nucleotides 18 (Xm) and 19 (G) in the sequence of tRNATyr (adapted from AG Helm, 
Mainz). (C-F) PBMCs from two to four donors were activated by transfection with the indicated tRNA 
(500 ng/ml) overnight. The different tRNAs had a 2’O-methylation at position 18 and were mutated at 
the same position, to different nucleobases. Cell-free supernatants were used to measure production of 
(C) IFN-α, (D) IL6, (E) TNF, and (F) IL12p40 by ELISA. Data were normalised to the unmodified 
tRNA transcript to avoid donor dependency. Each dot in the figure represents the mean of duplicates 
from one donor, and the blue lines represent the mean of all donors. nt, untreated negative control; 
*p<0.05; ***p<0.001  
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In summary, these results indicated that the nucleobase itself was less important for lack of 
induction, as long as it was not cytidine. All variants tested, including a methylated ribose and 
a downstream purine, led to efficient immunosilencing. The only exception was cytidine. 
Compared to the unmethylated tRNA, 2’O-methylated cytidine at position 18 did lead to 
silencing but less efficiently than the other nucleosides, and with strong donor variability 
(Figure 5-27). We therefore believe that the functional motif for immunosilencing is DmR, 
where D is any nucleobase except cytosine and R is a purine. This dinucleotide motif appears 
to be necessary for silencing of the induction of IFN-α and IL6 expression, but not for 
silencing of induction of TNF and IL12p40 expression, where the 2’O-methylation itself 
appears to suffice. This might indicate different motif specificities for TLR7 and TLR8. 
5.2.4 Location of the 2’O-methylated nucleobase in tRNA is not crucial for 
abrogation of stimulation 
In the experiments above, the 2’O-methylation was always present in the D-loop of tRNATyr. 
Only the methylated nucleoside itself or the nucleoside +1 upstream of the methylation was 
permutated. 
Next, we wanted to know whether the methylated motif could be transposed to a completely 
different structural context within the same tRNA, and thereby keeping its characteristics to 
act immunosilent. To test this, the methyl group was transposed to two other loop regions of 
the tRNA, at position 34 and position 57 in the anticodon loop and T-loop, respectively. 
Methylation of G34 occurs naturally in eukaryotic tRNAPhe 194 while methylation at G57 has 
not been detected so far in native tRNAs. The nucleobase following the methylation was 
mutated to determine whether the sequence motif for immunosilencing was the same at 
different positions inside the tRNA.  
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Fig. 5-28: Methylations in the T-loop showed the same sequence preference for 
immunosilencing. (A) Location of nucleotides 56 and 57 in the three-dimensional model of tRNATyr 
(adapted from AG Helm, Mainz). (B) Location of nucleotides 56 (Gm) and 57(Y) in the sequence of 
tRNATyr (adapted from AG Helm, Mainz). (C-F) PBMCs from two to five donors were activated by 
transfection with the indicated tRNA (500 ng/ml ) overnight. The different tRNAs contained a  
2’O-methylation at position 57, and position 58 was mutated to different nucleobases. Cell-free 
supernatants were used to measure production of (C) IFN-α, (D) IL6, (E) TNF, and (F) IL12p40 by 
ELISA. Data were normalised to the unmodified tRNA transcript to avoid donor dependency.  
Each dot in the figure represents the mean of duplicates from one donor, and the blue lines represent 
the mean of all donors. nt, untreated negative control; ***p<0.001 
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For the transposition of the methyl group to position 57 in the tRNA, the new location in the 
three-dimensional structure and the sequence is shown in Figure 5-28A and Figure 5-28B, 
respectively. The induction of cytokines by the different tRNA variants is shown in  
Figure 5-28C–F. In the native context of the tRNA, Gm57 was followed by an adenosine and 
led to no or only slight induction of cytokine secretion for all cytokines tested. Changing of 
the adenosine at position 58 to a guanosine gave no cytokine induction. Incorporation of a 
uridine at position 58 increased the secretion of IFN-α and IL6, but only the secretion of  
IFN-α was significant. For TNF and IL12p40, no induction was observed. Mutation of 
position 58 to a cytidine led to increased induction of IFN-α and IL6. For TNF, only cells 
from one donor out of four increased their cytokine production, while no induction was 
observed for IL12p40.  
In summary, the induction of cytokines showed similar patterns to the permutations at position 
G19, indicating that an immunosilencing motif could be transposed to other regions of the tRNA. 
In most species Gm34, a naturally occurring methylation in eukaryotic tRNAPhe, is followed 
by an adenosine. In the tRNA of E. coli, a uridine is present at position 35. The location of the 
methylated sequence motif in the three-dimensional structure and the sequence is shown in 
Figure 5-29A and B, respectively. The previous results forecast that this tRNA variant would 
induce some cytokine production. The cytokine induction by Gm34 with different variations 
at position 35 is shown in Figure 5-29C–F. The native sequence GmU induced cytokine 
secretion for all cytokines tested, as expected. Mutation of uridine at position 35 to adenosine 
or guanosine reduced the signal compared to Gm34U. This decrease was significant for both 
IFN-α and TNF induction, and significant with GmA for IL6 production. The cytokine 
production was increased for GmC, even though the signals were highly donor-dependent. 
For IL6, great donor variation was observed. For all donors, GmU and GmC induced higher 
amounts of the cytokine than GmG and GmA, but cells from two donors had similarly low 
production for all tRNA variations while cells from the other two produced amounts of 
cytokines that were around 10 times higher than with the transcript. 
The results supported our previous observations, suggesting that for immunosilencing in the 
context of IFN-α production, the motif DmR is functional at different positions in a tRNA  
˗ and highlighting the relevance of this motif for TLR7 activation in pDCs.   
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Fig. 5-29: Methylations in the anticodon loop showed the same preferences for immunosilencing. 
(A) Location of nucleotides 34 and 35 in the three-dimensional model of tRNATyr (adapted from AG 
Helm, Mainz). (B) Location of nucleotides 34 (Gm) and 35(Y) in the sequence of tRNATyr (adapted 
from AG Helm, Mainz). (C-F) PBMCs from two to five donors were activated by transfection with the 
indicated tRNA (500 ng/ml) overnight. The different tRNAs contained a 2’O-methylation at position 
34, and position 35 was mutated to different nucleobases. Cell-free supernatants were used to measure 
production of (C) IFN-α, (D) IL6, (E) TNF, and (F) IL12p40 by ELISA. Data were normalised to the 
unmodified tRNA transcript to avoid donor dependency. Each dot in the figure represents the mean of 
duplicates from one donor, and the blue lines represent the mean of all donors. nt, untreated negative 
control;  *p<0.05; **p<0.01; ***p<0.001   
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5.2.5 Immunoinhibitory potential of the immunosilencing motif 
It has been shown that the non-stimulatory effect of native tRNATyr is paralleled by an 
additional inhibitory effect on co-transfected stimulatory RNA 123. To determine whether this 
effect could be confirmed for other tRNA variants with immunosilencing properties,  
a selection of the previously tested tRNAs were used for co-transfection along with the 
unmodified transcript, and IFN-α production was measured by ELISA. The results are shown 
in Figure 5-30. The first data entry in the bar chart corresponds to where the stimulatory 
transcript alone was blotted; the stimulation of all other samples were normalised to this. 
After adding Gm18G and Gm19G the stimulation decreased, indicating an inhibitory effect. 
The tRNAs containing the motifs Gm18C and Gm19C were stimulatory on their own, and 
therefore no inhibition was expected. The amount of IFN-α was higher than with the 
transcript alone. Two other tRNA mutants that showed immunosilencing in Figure 5-24 were 
tested for immune inhibition. They were able to reduce the IFN-α signal from the transcript. 
We therefore believe that the motif DmR is not just immunosilent, i.e. is not recognised by the 
receptor, but antagonises the immune-activation properties of unmodified RNA. 
 
Fig. 5-30: Immunosilent tRNA mutants are 
able to inhibit stimulation by transcript. 
PBMCs of two to five donors were activated 
by co-transfection with 500 ng/ml tRNA and 
in-vitro transkript. ELISA was used to 
measure production of IFN-α. Data represent 
mean + SD for six independent donors 
normalised to transcript alone (-); **, p<0.01 
 
 
 
 
 
- GmG GmC GmC GmG AmG UmG
0.0
0.5
1.0
1.5
2.0
+ transcript
**
*** ***
tRNATyr
18 19 18 19 18 19 18 19 18 19 18 19
hI
FN
-
α
 
(n
o
rm
a
liz
e
d 
to
 
tr
a
n
s
c
rip
t)
Results 
 
82 
 
5.2.6 Summary of part 5.2 
In the previous section, tRNATyr was mutated at different locations to achieve a better 
understanding of the motif responsible for immunosilencing.   
First, the influence of the three-dimensional structure was analysed. By mutating the 
nucleosides at position 55 and 56 to guanosines, hydrogen bonding was disrupted and folding of 
the tRNA was destroyed 205, but the immunosilencing effect of the methylation was unchanged.  
Permutation studies were performed at three locations in the D-loop, the anticodon loop, and 
the T-loop concerning the nucleobase at the methylated ribose and the 3’ downstream nucleo-
base. The results indicated that a purine base at the position 3´ of the methylated ribose leads 
to the greatest silencing effect. Furthermore, pyrimidines affect the immunosilencing adversely, 
but cytosine more than uracil. For all stimulatory tRNAs, high donor variations were observed.  
Selected tRNAs were further tested for immune inhibition. All the immunosilent tRNAs tested 
were able to reduce IFN-α production by stimulation with the unmodified, stimulatory transcript.  
Thus, a methylated dinucleotide DmR (where D is A, G, or U but not C; R is a purine) could 
be identified that is responsible for the immunosilencing effect and can also lead to inhibition. 
This dinucleotide sequence can be found in a wide range of bacterial tRNAs, especially in 
many E. coli tRNAs such as tRNAGln, tRNAArg, and tRNASer, and also in B. subtilis tRNAPhe 
and S. typhimurium tRNAGly. 
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6 DISCUSSION 
RNA modifications play an important role in innate immunity to distinguish self RNA from 
foreign RNA. Modifications incorporated into RNA molecules can result in an abrogation of 
immunostimulation. In this study, E. coli tRNATyr was analysed in detail. It has been shown 
previously that 2’O-methylation at position G18 is sufficient and necessary for silencing of 
IFN-α production via TLR7 in pDCs. In this work, it was shown that 2’O-methylated RNA is 
also capable of inhibiting stimulation by RNAs that would otherwise have activating 
properties, and in a dominant manner. This dominant inhibitory effect was also shown for 
production of pro-inflammatory cytokines including TNF and IL12p40 by monocytes.  
This inhibition had similar efficiency to the inhibition of IFN-α. The inhibitory effect of  
2’O-methylated RNA was specific for RNA, as no other TLR ligands were inhibited.   
The results suggest a direct binding of the methylated RNA to TLR7, and strong competition 
with unmodified RNA. Furthermore, co-localisation of modified and unmodified RNA in 
endosomes was observed by microscopy.  
The sequence motif DmR was identified to be important for the immunosilencing effect. 
Here, D stands for all bases except cytosine and R indicates a purine. This RNA motif was 
found to be strictly necessary for inhibition of IFN-α and IL6 production, while TNF and 
IL12p40 production could to be silenced by most of the 2’O-methylated motifs and often 
resulted in great donor-related variation. 
6.1 Inhibition by 2’O-methylated RNA 
6.1.1 One 2’O-methylation in tRNATyr is sufficient for the immunosilencing 
effect  
For the first time, this study analysed the immunomodulatory effects of an RNA modification 
in its natural context, namely that of tRNA. It was found that the methylation at position 18 in 
E. coli tRNATyr is necessary and sufficient not only for silencing of immune activation, but 
also to act as a dominant inhibitor, resulting in inhibition of an otherwise stimulatory RNA 
(Figure 5-2). In other studies using siRNA as the model RNA, at least two positions were 
2’O-methylated in a 21-nucleotide RNA strand 187,190. One study screened for the minimal 
amount of 2’O-methylation necessary for immunosilencing. In that study, the authors 
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analysed siRNA strands with 1, 2, 3, or 5 methylations for their immune activation and 
immunoinhibitory capacity by transfecting PBMCs with them together with a stimulatory 
RNA strand. The 2’O-methylations were incorporated at positions with different nucleobases 
in the siRNA strand. The authors identified a single 2’O-methylation at adenosine in the 
siRNA as being immunosilencing and also immunoinhibitory for IFN-α production 206.  
This result is similar to the results in our study; only the nucleobase at the 2’O-methylated 
position differed. 
The gene trmH encodes the methyltransferase TrmH, which is responsible for methylation of 
G18 in bacterial tRNAs. This modification mediates the immunosilencing effect of E. coli 
tRNA preparations 123. Deletions of other methyltransferases (as done for TrmA or TrmB, 
incorporating m5U54 or m7G47, respectively) were unable to modulate the non-stimulatory 
characteristic of the E. coli tRNA preparation 124. This was analysed by introduction of 
isolated tRNAs of the deletion mutants into PBMCs and measurement of IFN-α. The tRNA 
preparations from TrmA and TrmB deletion mutants were unable to induce cytokine production, 
while the tRNA preparation from a TrmH deletion mutant induced IFN-α production 124.  
The gene encoding TrmH could only be found in gram-negative bacteria such as Salmonella 
typhimurium, Thermus thermophilus, and E. coli 179. Up to date, no methylation of G18 in 
gram-positive bacterial tRNAs could be detected 179. TrmK and TrmB are the only methyl-
transferases to have been identified in gram-positive bacteria to date (i.e. in B. subtilius). 
TrmK introduces a 1-methyl-adenosine at position A22 in tRNAs 179. Methylation at position 
18 by TrmH stabilises the structure of tRNA, and the immunomodulating effect is probably a 
positive side effect for the bacterium. However, all bacterial species tested except E. coli 
induced immune activation (Figure 5-4), indicating that immunosilencing modifications of 
tRNAs are not as prominent in all bacteria as in E. coli.  
It was also demonstrated in the present study that the whole tRNA is not necessary for 
inhibition, but rather that a small 27-nucleotide long fragment of the tRNA containing the 
2’O-methylation at position 18 is sufficient (Fig. 5-3). This indicates that even fragments of 
tRNA, for example after cleavage by RNase, would be able to suppress immune activation in 
infections. The 2’O-methylated fragment alone was not immunostimulatory; the same was 
true for the unmodified equivalent, which was used as control in the experiments. The total 
tRNA without any modifications was stimulatory, indicating that a minimum length was 
needed for stimulation. For inhibitory effects, smaller fragments are sufficient. By contrast, 
siRNAs with a length of 21–27 nucleotides could be recognised by TLR7 118,207,208.  
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Therefore, sequence composition may play a role in recognition ˗ as it has been shown that 
TLR7 has a preference for recognising GU-rich sequences 31,32,115. Double-stranded structures 
could also play an important role in immune activation, as speculated by Eberle et al. 187. 
After co-transfection with stimulatory RNA, IFN-α production was strongly reduced by 
inhibitory RNA and only minor effects were observed from control RNA. 
6.1.2 The role of type-I interferons in bacterial infections 
Most studies have analysed the non-stimulatory and inhibitory effects of modifications with 
respect to IFN-α stimulation via TLR7 in pDCs. TLR7 is known to be a receptor for viral and 
bacterial RNA 31,32,200. It is expressed in pDCs and leads to production of IFN-α upon 
activation. The IFN-α released binds to type-I interferon receptor and induces expression of 
hundreds of interferon-stimulated genes (ISGs) in the surrounding cells and tissues.  
These cells create an antiviral state, resulting in suppression of viral infection and onset of 
adaptive immunity 209,210. The key feature of the antiviral state is interaction of ISGs directly 
with the virus and the shutdown of the host protein translation machinery to prevent its use by 
the virus 211.  
Receptors such as TLR2 are capable of distinguishing between viral and bacterial proteins, 
which results in a different immune response 212. To investigate this, Barbalat et al. used 
HEK293 cells stably expressing TLR2 and different knock-out mice to exclude the activation 
of different TLRs 212. TLR2 can be activated by human cytomegalovirus 213,214, herpes 
simplex virus 215,216, hepatitis C virus 217, measles virus 218, and vaccinia virus 219, leading to 
production of type-I IFNs. In contrast, recognition of bacterial cell wall components leads to 
induction of pro-inflammatory cytokines including TNF and IL12p40. By isolating different 
subtypes of bone marrow and spleen cells, Barbalat et al. identified different cells responsible 
for TNF and Il12p40 secretion and for IFN-α secretion in response to TLR2 activation 212. 
Thus, the cell type is critical whether TLR2 can be activated by a viral or bacterial stimulus 212. 
In contrast, activation of TLR7 results in production of type-I IFN in response to both viruses 
and bacteria. The production of type-I IFNs not only influences the antiviral immunity; type-I 
IFNs are also capable of influencing the antibacterial immune response 220. It has been shown 
that low amounts of type-I IFNs prevent the intracellular replication of Legionella 
pneumophila in macrophages 221 and that type-I IFN treatment of mice that were 
intragastrically infected with Salmonella typhimurium reduced the lethality 222. Thus, type-I 
IFNs appear to be protective against infections with gram-negative bacteria. By contrast, 
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experiments with mice deficient in type-I IFN production have shown an increased resistance 
to lethal effects of LPS, indicating a contribution of type-I IFNs to the lethal septic shock 
syndrome 223. The underlying mechanism is elusive. For infections with gram-positive 
bacteria, treatment of mice with purified type-I IFN preparations or IFN-specific antibodies 
has indicated benefits of type-I IFNs for treatment of infections with Streptococcus 
pneumoniae 224. The same positive effect has been observed for human and murine 
macrophages infected with Bacillus anthracis 225. Upon treatment with type-I IFN, the cells 
were protected from the lethal effects of the bacterium and the intracellular spore germination 
was reduced. On the other hand, intravenous or intraperitoneal infection of mice deficient in 
IRF3, or signalling through IFNAR, indicated a reduction in host resistance in primary Listeria 
monocytogenes infections by the type-I IFN response 223. Thus, the type-I IFN response is not 
only important in viral infections but also plays a role in defence against bacterial infections. 
6.1.3 2’O-methylation inhibits production of pro-inflammatory cytokines 
Most studies have investigated the effect of RNA modifications on human pDCs in which 
IFN-α production is induced via TLR7. We found that 2’O-methylated RNA not only lacked 
and blocked IFN-α production, but also reduced the production of pro-inflammatory 
cytokines including IL12p40 and TNF (Figure 5-6). One other group observed an inhibition 
of IL6 production by double-stranded siRNAs in which one strand was 2’O-methylated and 
inhibited the stimulation by its unmodified counterpart 206. Another group observed inhibition 
of bRNA-mediated IFN-α induction by 2’O-methylated siRNA, but not inhibition of 
induction of TNF 200. The lack of effect on TNF production may have been due to possible 
contamination of bRNA preparations with cell wall components such as LPS. Unlike 
monocytes, pDCs do not express TLR4 and are therefore resistant to LPS contamination.  
As the bRNA-induced immunostimulation in that study was abolished upon treatment with 
RNase, possibly a synergism between cell wall components and RNA could have led to the 
strong TNF induction. The RNA preparations used here were isolated by a two-step 
procedure, first with TRIzol followed by isolation over a silica membrane. In the latter 
procedure, RNA mixed with chaotrope salts binds to the silica membrane. The bound RNA is 
washed and then eluted. As no cell wall components can bind, adequate washing results in 
pure RNA solutions.  
In the work for this thesis, one 2’O-methylated site was found to be sufficient to inhibit the 
stimulation of a wide range of cytokines including TNF, IL12p40, and IL6. By contrast,  
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in another study, a minimum of three methylated sites in siRNA was found to be necessary for 
inhibition of TNF production, while one methylation in 21 nucleotides was sufficient to 
inhibit IFN-α production 206. This effect might due to sequence specificity of the methylated 
motifs (see below).  
TLR7 was shown to be expressed mainly in pDCs secreting type-I IFNs and it is debated 
whether IL6 is also secreted by pDCs. Induction of TNF and IL12p40 production by bRNA 
probably has to take place in another cell type. Fractionation of PBMCs in CD14-positive 
monocytes and CD14-negative cells led to production of IFN-α only in the whole PBMC 
preparation and the CD14-negative fraction, while IL12p40, TNF, and IL6 were produced by 
the whole PBMC preparation and by the CD14-positive fraction (Figure 5-9). This indicated 
that monocytes were responsible for production of pro-inflammatory cytokines upon 
transfection with bRNA. It has already been shown that monocytes do not express TLR7,  
but rather high amounts of the RNA-sensing receptor TLR8. TLR8 is responsible for 
induction of pro-inflammatory cytokines in monocytes in response to viral RNA, with a 
preference for AU-rich sequences 102,152. Jöckel et al. were also able to detect production of 
IL12p40 and TNF in response to tRNA preparations in enriched monocytes 124. In addition, 
monocytes did not respond to imiquimod, a ligand specific for TLR7, indicating that no TLR7 
is expressed in monocytes. Thus, it appears that not only TLR7, but also TLR8 can be 
stimulated by bRNA and that this activation would be prone to inhibition by 2’O-methylated 
RNA. However, the sensing of bacterial RNA by human TLR8 in monocytes has not yet been 
proven, and it could be addressed using knock-down experiments. 
Taken together, the data support the influence of 2’O-methylation of RNA in suppression of 
immunostimulation induced by RNA. This suppression is especially important for self RNA, 
as self RNA should not activate the immune system. If the discrimination of self RNA and 
non-self RNA fails, self RNA can lead to immune activation ˗ resulting in an autoimmune 
disease. The immune diseases that result from recognition of self RNA are mainly SLE and 
psoriasis 149–154. In SLE, it has been shown that autoantibodies are produced 162.  
Here, differences in RNA modification in patients and in healthy individuals may play an 
important role, as preliminary data suggest (unpublished data). 
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6.1.4 The inhibitory effect of 2’O-methylated RNA is specific for stimulation 
with RNA  
As the inhibitory RNA appeared to block the stimulation of TLR7 and TLR8, the inhibitory 
effect might apply to other TLRs or small synthetic TLR7/8 ligands. Therefore the TLR 
ligands CpG, R848, and Pam3CSK4 (ligands for TLR9, TLR7/8, and the dimer TLR1/2, 
respectively) were used in co-transfections with the inhibitory RNA preparation and the 
cytokine production was measured (Figure 5-10). Inhibitory RNA might block the entry of the 
stimulatory agents or activate an inhibitory receptor influencing the activation of other TLRs. 
However, no reduction in stimulation by the different TLR ligands was observed. This result 
indicated that the inhibitory effect was specific for stimulation with RNA.  
Remarkably, we did not even observe an inhibition of the effect of R848, even though it 
activates both TLR7 and TLR8. This might due to different binding sites for R848 and RNA 
at the receptor, as reported by Colak et al 130. R848 is often described as a guanosine analogue, 
but the binding to its receptor clearly differs from that of the natural ligand. This might be due 
to the chemical composition or to the size. Colak et al. recently found that R848 induced 
different phosphorylation and transcriptional events after activating TLR8 compared to RNA. 
In addition, TLR7 and TLR8 recognise RNA and R848 by overlapping and non-overlapping 
recognition sites, and discriminate between both 130. To investigate this, TLR7 and TLR8 
were mutated at different positions of the ectodomains and activation by the two ligands was 
observed. It could be shown in this thesis that the inhibitory RNA binds directly to the 
receptor. R848 might still bind to TLR7 and TLR8 through different binding sites, resulting in 
an activation of the receptor even in presence of the inhibitory RNA.   
6.1.5 No other immunosilent RNA preparations were identified 
E. coli tRNA and T. thermophilus tRNA preparations have been shown to be non-stimulatory, 
resulting from 2’O-methylations incorporated in RNA nucleosides 124. This feature could 
influence the recognition of the whole bacterium by the immune system. It could therefore be 
used as an immune evasion mechanism 124. Identification of other non-stimulatory RNA prepara-
tions could help our understanding of the beneficial or harmful properties of some bacteria.   
Thus, different tRNA preparations were tested for their stimulatory capacity. In the work for 
this thesis, all the tRNA preparations tested induced IFN-α, IL12p40, and TNF production 
(Figure 5-5 and 5-8). The general ability of tRNA preparations to induce IFN-α in PBMCs 
was also described by Jöckel et al. 124. They also reported that different levels of cytokines 
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were induced by tRNA preparations from different species. In addition, they showed that 
tRNA preparations from E. coli Nissle and T. thermophilus lacked immune stimulation regarding 
IFN-α production 124, which might be exceptions to the rule. Both tRNA preparations were 
shown to inhibit the production of IFN-α induced by other immunostimulatory tRNAs, in a 
dominant fashion 124. Yet surprisingly, T. thermophilus tRNA has been found to induce produc-
tion of IL6 in human PBMCs 124. As T. thermophilus is a gram-negative bacterium, this might 
be due to LPS contamination activating TLR4. Other studies have also identified single 
tRNAs from Saccharomyces cerevisiae as being immunosilent. However, in contrast to the 
immunosilent tRNA preparations identified, where 2’O-methylation at position G18 could play 
an important role, the immunosilencing by mammalian tRNAPhe and tRNALys3 is independent of 
Gm18 123,179. This indicates that further immunosilencing modifications are used in native 
tRNAs, and are important. The exact modifications responsible have not been identified so far.  
As E. coli Nissle is known as a bacterium used for probiotics, Jöckel et al. discussed that the 
inhibitory effect of the tRNAs may support this effect 124. Probiotics should provide health 
benefits when being consumed. They modify the flora of humans and replace harmful bacteria 
with useful ones. E. coli Nissle is also used as therapeutic to treat chronic disease such as 
inflammatory bowel disease (IBD). Bifidobacterium bifidum is also known for probiotics and 
it can be used to rebuild a healthy flora in the colon. In the present study, the tRNA 
preparation of Bifidobacterium bifidum induced IFN-α production. The effect observed by 
Jöckel is therefore not true for all probiotic bacteria.  
The stimulatory effects of all the RNA preparations tested could be inhibited by  
co-transfection with inhibitory 2’O-methylated RNA, indicating that the inhibition is not 
specific for tRNA or RNA from a defined species. In addition, the group of Bauer showed 
that stimulation by RNA from influenza A virus ˗ which triggers TLR7 activation ˗ could also 
be inhibited by 2’O-methylated RNA 124.   
All tRNA preparations tested induced cytokine production, but at different levels, ranging 
from 1–2.5 ng/ml IFN-α, 300–1,000 pg/ml IL12p40, and 200–800 pg/ml TNF when 
excluding the outlier Bacillus subtilis. To screen the low-stimulatory preparations for non-
stimulatory or even inhibitory single tRNAs, fractionation of the preparations could be done. 
This could, for example, be performed by size-exclusion chromatography. The resulting 
fractions could then be tested for their stimulatory potential, and non-stimulatory fractions 
could be screened for their exact content, especially for modifications.   
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6.2 The mechanism of inhibition indicates direct binding of  
2’O-methylated RNA to TLR7 
To investigate the mechanism of inhibition, we analysed the downstream signalling of TLR7 
and TLR8 upon RNA stimulation and the expression of mRNA for different cytokines.  
We found that the inhibitory effect of the 2’O-methylated RNA could be observed at the level of 
mRNA expression as well as at the level of MAPK and NFκB activation (Figures 5-13 and 5-14). 
The decrease in activation was observed at early time points, while the control RNA failed to 
inhibit the activation, indicating that the 2’O-methylated RNA interacted directly with the 
receptor. The results also indicated that R848 induced activation within the first 60 min, 
whereas stimulation with RNA was not apparent before 120 min. The cellular uptake of the 
small molecule R848 differs from that of the encapsulated RNA, resulting in different 
activation times (Figure 5-13). In addition, the observation that co-transfection with 
stimulatory and inhibitory RNA was necessary for proper inhibition indicated direct 
competition at the receptor ˗ or a need for spatial restriction of an inhibitory receptor to the 
stimulated one ˗ to inhibit the activation directly (Figure 5-15). Sequential uptake of RNA was 
observed in live-cell imaging of fluorescent-labelled RNA at later time points (Figure 5-19). 
The fluorescence was first located in dot-like structures, before showing release into the 
cytoplasm. The signal vanished after a while, before dot-like structures could again be seen. 
This indicated that there was repeated cellular uptake of RNA-containing liposomes and 
release of RNA into the cytoplasm. This could explain the differences in stimulation observed 
for time-delayed addition of stimulatory and inhibitory RNA. A 50% inhibition for 
transfection with the inhibitory RNA 3 h after the stimulatory one was also observed by 
Hamm et al. for production of IFN-α and TNF in human PBMCs 206. 
6.2.1 2’O-methylated RNA probably competes with stimulatory RNA for 
receptor binding 
Co-immunoprecipitation experiments with 2’O-methylated or unmethylated RNA and TLR7 
illustrated that the inhibitory RNA probably bound directly to TLR7. We showed that 16S 
rRNA bound to TLR7 (Figure 5-16). 16S rRNA could be displaced by adding inhibitory 
RNA. To determine the amount of 16S rRNA bound to TLR7, the RNA was pulled down 
with TLR7 and isolated. The resulting RNA was reverse transcribed to DNA for analysis by 
qPCR. Some 16S rDNA strands were also detected in the negative sample, where no RNA 
was used for transfection. This might be due to known contamination of the reagents used for 
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isolation and synthesis. Most of the enzymes used are produced by recombinant techniques in 
bacteria, so the enzymes isolated may have contained bacterial nucleic acids recognised by 
the primers used, which detected conserved regions of the 16S rDNA sequence 226.  
In a second approach, TLR7 was detected after pull-down with biotinylated RNA (Figure 5-17). 
In this way, it could be shown that TLR7 bound to the unmodified RNA. On the western blot, 
TLR7 co-immunoprecipitated with RNA was detected as two bands that migrated faster than 
TLR7 alone. This observation might suggest that there was cleavage of the receptor. In 2011, 
Ewald et al reported that TLR9 was cleaved during processing in endosomes 227. The same 
was found for TLR3 and TLR7 227. TLR7 was cleaved twice on the way from the ER to the 
endosome. This might explain our own observations. As the HA tag was detected by our 
antibody, only the parts of TLR7 that were still attached to the tag would be detected. As two 
bands were observed, the upper band could be the cleavage product of the first cutting, while 
the lower band may have been the result of two cleavages. The TLR7 pulled down with  
anti-HA beads binds to the beads after cell lysis. Thus, it could also be located in the ER 
before lysis where it is still uncleaved.  
To demonstrate that the inhibitory RNA not only replaced the stimulatory RNA from the 
receptor but bound directly to the receptor, biotinylated tRNA with and without Gm18 was 
used for co-immunoprecipitation with TLR7 (Figure 5-18). Both tRNAs were able to pull 
down TLR7, indicating that both RNAs bound directly to the receptor. The amount of the  
co-immunoprecipitated protein was similar in both approaches. Again, the displacement of the 
unmodified tRNA through the methylated tRNA was investigated. Biotinylated tRNA 
carrying or not carrying a 2’O-methylation at G18 was used for co-transfection with its 
unbiotinylated counterpart. The results clearly indicated that the methylated RNA could 
displace the unmodified one from the receptor, but not vice versa. The biotinylated, 
unmodified RNA was unable to pull down TLR7 when 2’O-methylated RNA was present.  
On the other hand, biotinylated 2’O-methylated RNA precipitated the same amount of TLR7 
in the presence and absence of unmodified RNA. Together, these data indicate a stronger 
binding affinity of 2’O-methylated than of unmethylated tRNA for TLR7, as the  
2’O-methylated tRNA was able to displace the unmodified tRNA. Therefore, we believe that 
the 2’O-methylated RNA binds directly to the receptor, blocks it, and hinders activation by 
stimulatory RNA as shown in Figure 6-1. The assay used is limited, due to the receptor being 
located in the endosomes, RNA reaching the endosomes, and the sensitivity of the analysis.  
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The binding of 2’O-methylated RNA to TLR7 was also 
investigated by Hamm et al. They used 2’O-methylated 
and unmodified siRNA with a human TLR7 protein in an 
amplified luminescent proximity homogenous binding assay 
(AlphaScreen™). They observed a very efficient binding 
of 2’O-methylated siRNA to TLR7, while the unmodified 
counterpart bound more weakly 206. The binding was 
observed separately for the 2’O-methylated and unmodified 
siRNAs, and no direct competition of the siRNAs at TLR7 
was studied. Other studies have investigated the 
stoichiometry and structural constitution of the RIG-I-
dsRNA complex by gel filtration and scanning force 
microscopy 228. Thus the ligand-receptor complex was 
filtrated and the different fractions were analysed with 
photometry. By shifting the peaks for protein or nucleic acid detection, the binding of the two 
components could be shown. By using scanning force microscopy, a model of the complex 
surface was produced, enabling conclusions about the ratio of ligand to receptor in the 
complex. 
The efficiency of binding of the inhibitory RNA to TLR7 and TLR8 was slightly different,  
as titration studies indicated (Fig.5-11). PBMCs were stimulated with bRNA involving  
co-transfection with different amounts of inhibitory RNA. Production of IFN-α, TNF,  
and IL12p40 was measured and the IC50 calculated. The IC50 to inhibit 1 µg/ml stimulatory RNA 
was calculated as 0.06 µg/ml at TLR7, while the IC50 at TLR8 was calculated as 0.01–0.02 µg/ml, 
indicating that the inhibitory RNA might have a stronger affinity for TLR8 than for TLR7. 
The concentration of the inhibitory RNA at IC50 corresponds to 1/50 to 1/100 of the 
stimulatory concentration for TLR8. Other groups have also analysed the inhibition;  
they came up with an IC50 of 15–5 nM for all cytokines and receptors, reflecting 1/65 to 1/200 
of stimulatory RNA concentration 206, which is therefore comparable to our own data.  
The IC50 of the unmethylated control RNA was also calculated in our study. It was around  
10 times higher, indicating that the 2’O-methylated RNA had a higher affinity for the receptor 
than the unmethylated one.  
 
Fig. 6-1: Overview of the 
proposed mechanism of immuno-
inhibition. The inhibitory RNA 
binds to the receptor in human 
PBMCs, avoids activation, and 
blocks it from activation by 
stimulatory RNA.  
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6.2.2 2’O-methylated and unmodified RNA co-localise in liposomes and 
endosomes  
The efficiency of the co-transfection was assessed in microscopy experiments. Thus, methylated 
and unmodified RNA labelled with different fluorescent dyes (ATTO488 and ATTO590) 
were used to co-transfect murine DCs and live-cell analysis was performed for 6 h. The two 
fluorescent-labelled RNAs were mixed before packaging with lipofectamine. Co-localisation 
was observed in dot-like structures outside and inside the cells, indicating location in 
liposomes and endosomes, respectively. Thus, both RNAs appeared to reach the same 
endosomes and could therefore compete for receptor binding. The location in endosomes was 
not shown unequivocally. 
Surprisingly, a release of the fluorescence in the cytoplasm was observed, resulting in distinct 
localisation of the different dyes. While ATTO488-labelled RNA was located mainly in the 
cytoplasm, ATTO590-labelled RNA migrated to the nucleus. This localisation was dye-
dependent and independent of the modification, as experiments with switched dyes resulted in 
the same distribution of fluorescence. Migration of transfected nucleic acids into the nucleus 
was also observed by Fisher et al. 229 and Leonetti et al. 230 in their studies using microinjection 
experiments in non-immune cells. A migration not only of DNA, but also of RNA,  
as observed here, might be possible due to passive diffusion through the nuclear membrane. 
Oligonucleotides of up to 100 bp can diffuse passively through the nuclear core complex 231; 
for molecules, the diffusion limit has been shown to be 40 kDa 232. This diffusion is independent 
of concentration, temperature, and ATP levels 231. The green fluorescent signal from 
ATTO488-labelled RNA was distributed in the cytoplasm. This might have been due to the 
size of the dye. ATTO488 is a larger molecule than ATTO590, and coupled to the RNA this 
might result in a molecule larger than 40 kDa ˗ the size limiting diffusion into the nucleus. 
Both fluorescent dyes are positively charged, but show differences in molecular structure;  
thus, dye-specific differences could have influenced the distribution. However, both fluorescence 
signals vanished after a while. This might have been due to degradation of the RNA and the 
fluorescent dye attached. The half-life of free DNA inside a cell averages 1–2 h, while DNA 
packed in lipoplexes remains stable for a longer time 233,234. This encapsulation might explain 
that after degradation of nucleic acids in the cell, further lipoplexes could fuse with the cell 
and intact RNA would again be released in the cytoplasm. It has been shown in HeLa cells 
that all microinjected mRNA ends up in the nucleus, irrespective of the compartment into 
which the mRNA was injected. In contrast, the microinjection of tRNA strands resulted in 
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cytoplasmic localisation. This was observed for tRNAs injected into the cytoplasm as well as 
into the nucleus. The export of all tRNAs in the cytoplasm was attributed to the tRNA export 
system, which also exported unnatural tRNAs when they were introduced in high amounts 235.  
In the present work, we observed a periodic release of the RNA into the cytosol from dot-like 
structures, followed by complete dissappearance of any signal, after which dot-like structures 
could again be observed. The RNA was packed in liposomes for transfection, visible as dot-
like structures around the cells. After uptake into the cells, dot-like structures could again be 
observed, indicating their localisation in endosomes and endolysosomes.  
To visualise the distribution of RNA, murine DCs were used in our study, as they are immune 
cells with a relatively large cytoplasm. However, as shown later, murine cells were not 
consistently inhibited by the RNA modification used. This might be due to the importance of 
TLR13 in murine immune cells. TLR13 has been shown to sense one specific sequence, 
which is conserved in 23S rRNA of bacteria 36. Incorporation of N-6 methylation at a distinct 
position inside this sequence mediated an immunosilencing effect. The RNA sequences used 
for microscopic analysis were stimulatory in human cells. Therefore, live-cell experiments 
with human PBMCs would be a more appropriate model to study RNA distribution. PBMCs 
are a mixture of different cells, and only a subset of them is stimulated by the RNA. To obtain 
a more unique cell population, distinct populations should be isolated beforehand, such as 
monocytes or pDCs. However, both cells are known to have a large nucleus surrounded by 
only a small cytoplasm. Inside these cells, the distribution of fluorescent-labelled RNA inside 
the cytoplasm would be difficult to observe. Other human cells with a large cytoplasm should 
be used, but if they are not specialised immune cells the distribution might differ because no 
recognition via TLRs would take place in these cells. Alternatively, the imaging could be 
done with RNA containing an N-6 methylation, using murine cells to observe differences for 
the murine system.  
6.3 Inhibitory RNA in the murine system 
As the blocking of cytokine production by co-transfection with stimulatory RNA and the  
2’O-methylated inhibitory RNA showed clear results in the human system, and as TLR7 in 
the murine system is known to have similar specificities to the human one, the same effect 
was studied in murine immune cells. The results were not as clear as in the human cells.  
In many cases the blocking of cytokine secretion by 2’O-methylated RNA could be observed, 
but not in all experiments and it was not as prominent as in the human system. In particular, 
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Fig. 6-2: Structure and location of 
different RNA modifications. (A) N-6 
methylation of adenosine. (B) 2’O-
methylation of the ribose in guanosine 179.  
differences were observed between different batches of GM-CSF-containing conditioned 
medium generated by the plasmacytoma X63 cell line, which was used for generation of bone 
marrow-derived DCs. In other studies, using murine FLT3L-DCs, inhibition of IFN-α and 
IL6 expression by 2’O-methylated RNA was detected 206. The FLT3L-DCs used are the 
murine-equivalent cells to human pDCs and they are known to express TLR7, while in our 
study DCs generated with GM-CSF were used (cDCs). The cells generated could have 
differed depending on different batches of the differentiation medium, as we could not ensure 
that an identical amount of GM-CSF was present. cDCs express TLR13 and produce pro-
inflammatory cytokines including IL12p40 and TNF. pDCs express TLR7 and are the main 
producer of type-I IFN.                                                                                                                                                                               
We checked the TLR levels of cells generated with 
different batches of GM-CSF. While the levels of 
TLR7 and TLR13 showed only small differences, 
TLR3 was expressed at high levels in one sample, 
and almost no TLR3 expression could be detected 
in the other one. While inhibition was observed in 
the cells with less TLR3, no inhibition was detected 
in cells expressing high levels of TLR3. TLR3 is 
known to detect double-stranded RNA. Thus, it is possible that the RNA used activated TLR3 
under certain circumstances or that the 2’O-methylated RNA bound to TLR3 with high 
affinity and could therefore not block other receptors. This would then indicate that TLR3 
could not be inhibited by methylated RNA. Stimulation of the cells with polyI:C, a ligand for 
TLR3, was not tested.  
Furthermore, the ratio of expression of TLR7 and TLR13 could play a role. While TLR7 
senses ssRNA, TLR13 recognises one specific sequence. This sequence is conserved in 23S 
rRNA of bacteria and is therefore present in the bRNA preparation that we used.  
The sequence stimulating TLR13 can be silenced by incorporation of an N-6 methylation at a 
defined adenosine 36; the methylated base is shown in Fig. 6-1A. In the present study, we used 
2’O-methylation of guanosine to inhibit immune activation (shown in Fig. 6-2B). Different 
modifications are probably responsible for inhibition of the different receptors, namely N-6 
methylation for TLR13 and 2’O-methylation for TLR7. 
Also, the role of cytosolic RNA receptors was not investigated and they could also play a role 
in the stimulation by the RNA introduced by transfection. If this is true, it should be 
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determined whether their activation can be inhibited by any modification. As RNA is 
introduced with cationic lipoplexes into the cells, it cannot be checked that the RNA is 
specifically delivered into endosomes. As observed by microscopy, RNA was released into 
the cytoplasm were cytosolic receptors could be activated. But, stimulation of cytosolic 
receptors mainly results in production of type-I IFNs. As the activation of TNF and IL12p40 
production was measured, an activation of TLRs is more likely as they are known to induce 
pro-inflammatory cytokines including TNF and IL12p40. 
To investigate this issue further, experiments could be performed by co-transfection with 
stimulatory RNA together with 2’O-methylated and N-6 methylated RNA to inhibit TLR7 
and TLR13 in murine cells. As TLR13 recognises only a specific sequence in 23S rRNA, 
RNA preparations lacking the 23S rRNA could be used for stimulation.   
6.4 Identification of an immunosilencing modification motif 
In the last part of this work, a sequence motif responsible for the immunosilencing effect was 
studied. We found that the three-dimensional structure stabilised by the 2’O-methylation at 
guanosine 18 probably had no influence on the immunosilencing capacity of the tRNA 
(Figure 5-24). This may be because RNA is recognised in the endosomes inside the cell. 
Endosomes fuse with lysosomes, which are specialised in destroying invading pathogens.  
The low pH inside the vesicular bodies 236 may lead to destruction of the hydrogen bonds 
stabilising the three-dimensional structure of the tRNA. Thus, the three-dimensional structure 
might be destroyed in the vesicle where it meets TLR7.  
Permutation studies of the methylated nucleoside indicated that all nucleosides except 
cytidine led to immunosilencing (Figure 5-25 - 5-27). For the base following the methylation, 
a purine (guanine or adenine) was identified to be important for the immunosilencing effect. 
This raised the question of whether the methylation at position 18 formed an inhibitory motif 
or whether it destroyed a stimulatory motif. TLR7 was shown to recognise GU-rich sequences 
and TLR8 has been found to prefer AU-rich sequences. According to our data, incorporation 
of a 2’O-methylation in AU or GU motifs resulted in a stimulation. This indicates that the 
immunosilencing effect is not due to disturbance of a recognised sequence by incorporation of 
a 2’O-methylation.  
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 Comparison with other studies that used 2’O-methylated RNA for inhibition confirms the 
relevance of the sequence motif identified. Hamm et al. analysed siRNAs with different 
amounts of 2’O-methylation for their immunosilencing and immunoinhibitory capacity when 
annealed to an unmodified strand. They transfected PBMCs with the siRNAs and analysed the 
supernatants for IFN-α and TNF production. The study indicated that one 2’O-methylated 
nucleoside would be sufficient for immunosilencing of IFN-α and TNF production when 
transfecting with the 2’O-methylated siRNA strand alone. After transfection with the annealed 
siRNA (the 2’O-methylated strand plus the unmodified strand), three 2’O-methylated 
nucleosides were found to be necessary for inhibition of TNF production 206. A closer look at 
the sequence of the 2’O-methylated siRNA used indicated that the first methylation resulted 
in an AmC motif. A cytidine located at position +1 upstream of the methylation influenced 
inhibition negatively in our experiments. The second methylation incorporated by Hamm et al. 
resulted in the motif CmC. Based on the data presented in our study, incorporation of CmC 
within siRNA would have no inhibitory activity. To introduce the third methylation, the 
second one was shifted to a CmG motif. The third methylation resulted in an AmA. This third 
modification, according to our data, would be the most efficient one for immunosilencing and 
inhibition. So it was not surprising that incorporation of three 2’O-methylations was necessary 
to obtain a dominant immunoinhibition for the cytokines tested. Incorporation of the third 
methylation alone should have the same effect and should silence the stimulation. Our data 
indicate that 2’O-methylation alone is not sufficient but that the sequence motif also plays an 
important role. This could be used for RNA-based therapeutics, in which one 2’O-methylation 
at the correct position could be sufficient to avoid stimulatory side effects and a modification 
of the whole RNA would not be necessary. This could minimise 
unwanted interactions between incorporated modifications and could 
make generation and synthesis of siRNAs easier. siRNAs as drugs 
against different cancers and viral infections are being tested in 
different clinical trials 237. It was also speculated by Eberle et al. that 
by incorporation of the methyl group, the binding of hydrogen bonds 
by the 2’OH group is abolished. The methylation further reduces the 
chance that the 2’OH group can act as H-bond acceptor 187. 
Furthermore, the 2’O-methylated motif was shifted to two other 
positions inside the tRNA as indicated in Figure 6-3 (Figure 5-28 
and 5-29). At all positions similar motif specificities were observed. 
 
Fig. 6-3: Sequence of 
E.coli tRNATyr with 
the methylation sites 
indicated in red.  
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This contradicts the hypothesis of destroying a stimulatory motif by 2’O-methylation.  
Three different positions in the tRNA were 2’O-methylated leading to an immunosilent RNA, 
indicating that all three positions had to be stimulatory before, resulting in a minimum  
of three stimulatory motifs. For disturbing all stimulatory motifs a minimum of three  
2’O-methylations have to be incorporated. However, in each tRNA version tested, only one 
motif was 2’O-methylated. The other two motifs would remain stimulatory. In this case, the 
stimulation of the tRNA would potentially be reduced compared to the unmodified one, but 
no complete silencing would be expected. Furthermore, silencing of a stimulatory motif 
would not inhibit the stimulation by other RNA strands. Therefore, generation of an inhibitory 
motif by 2’O-methylation is more likely. 
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6.5 Outlook 
In the present work, we analysed inhibition of TLR7 and TLR8 signalling by 2’O-methylated 
RNA. The involvement of TLR8 was not formally proven in this study. For verifying this, knock-
down experiments in primary cells could be performed and TLR8 could be overexpressed in 
HEK cells and checked for NFκB activation. Preliminary data indicate that there is direct 
binding of the 2’O-methylated RNA to TLR7. This should be verified by other methods using 
the isolated receptor. AlphaScreen™ analysis or gel filtration could be used. TLR8 should also 
be examined in the same way.  
The dinucleotide motif identified to be responsible for immunosilencing of E. coli tRNATyr 
was tested at different positions inside the tRNA. It could be incorporated into tRNAs of other 
bacterial species to determine whether the motif is generally responsible for immunosilencing or 
whether the effect observed is specific for E. coli tRNA. Also, the amount of 2’O-methylation  
at position G18 in whole tRNA preparations of different species ˗ bacterial, fungal, and 
mammalian ˗ could be analysed and correlated with their stimulatory capacity. This would 
indicate the importance of this specific modification in discriminating between self and non-self 
structures. 
tRNAs of the fungus Saccharomyces cerevisiae (tRNAPhe, tRNALys3) were identified to be 
immunosilent independently of Gm18. Here, the modification responsible could be identified 
and compared to Gm18.  
To understand the relevance of RNA modifications in autoimmune disease such as SLE, 
RNAs released by apoptotic cells from SLE patients could by analysed for the amount and 
kind of modifications, and compared to those from healthy individuals. In SLE patients, self 
RNA activates immune receptors resulting in the formation of autoantibodies. Preliminary 
analyses in this field indicate that there are differences in the frequency of some modifications.  
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